Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 754. Отображено 193.
14-05-2018 дата публикации

СРЕДСТВО, УСИЛИВАЮЩЕЕ СОЛЕНЫЙ ВКУС, И СПОСОБ ИЗГОТОВЛЕНИЯ, И СПОСОБ УСИЛЕНИЯ СОЛЕНОГО ВКУСА

Номер: RU2653735C2

Изобретение относится к пищевой промышленности, а именно к композиции, усиливающей соленый вкус. Композиция включает соединение, представленное любой из приведенных ниже общих формул (2)-(6) или его соль, и наполнитель:При этом Q представляет собой гетероатом, q представляет собой 0 или 1; m и n, каждый из них, представляют собой целое число от 1 до 4, и m+n представляет собой целое число от 3 до 5; m' и n', каждый из них представляют собой целое число от 1 до 3, и m'+n' представляет собой целое число от 2 до 4; и k представляет собой целое число от 0 до 3. Изобретение относится также к пищевой добавке, приправе, пищевому продукту и напитку, включающему любое из вышеуказанных соединений или их соли. Изобретение относится к пищевому продукту и напитку, включающему 10 миллионных долей или более любого из вышеуказанных соединений или их солей. Изобретение относится к способу усиления соленого вкуса пищевого продукта и напитка, включающему стадию добавления любого из вышеуказанных соединений ...

Подробнее
20-09-2009 дата публикации

ПОЛИАМИНЫ, ИСПОЛЬЗУЕМЫЕ ПРИ ПРОТИВОПАРАЗИТАРНЫХ И ПРОТИВОРАКОВЫХ ТЕРАПИЯХ И В КАЧЕСТВЕ ИНГИБИТОРОВ ЛИЗИН-СПЕЦИФИЧЕСКОЙ ДЕМЕТИЛАЗЫ

Номер: RU2008108632A
Принадлежит:

... 1. Соединение, имеющее формулу, выбранную из группы, состоящей из: ! , ! , ! , ! , ! , ! , ! , !и ! ! где n является целым числом от 1 до 12; ! m и p независимо являются целыми числами от 1 до 5; ! q является 0 или 1; ! каждый R1 независимо выбирается из группы, состоящей из C1-C8 замещенного или незамещенного алкила, С6-С20 замещенного или незамещенного арила или гетероарила и C7-C24 замещенного или незамещенного аралкила или гетероаралкила; ! каждый R2 независимо выбирается из водорода или C1-C8 замещенного или незамещенного алкила; ! R3 и R4 независимо выбираются из группы, состоящей из водорода, C1-C8 замещенного или незамещенного алкила, С6-С20 замещенного или незамещенного арила и C7-C24 замещенного или незамещенного аралкила; ! R5; R9, R6, R7 и R8 независимо выбираются из группы, состоящей из водорода и C1-C8 замещенного или незамещенного алкила; ! группами A, R10 и R11 независимо является (CH2)1-5 или этен-1,1-диил; ! R12 и R13 независимо выбираются из группы, состоящей из водорода ...

Подробнее
06-07-2006 дата публикации

Verfahren zur Herstellung von Onium-Salzen mit Alkyl- oder Arylsulfonat-Anionen oder Alkyl- oder Arylcarboxylat-Anionen mit geringem Halogenid-Gehalt

Номер: DE102004060076A1
Принадлежит:

Die Erfindung betrifft ein Verfahren zur Herstellung von Onium-Salzen mit Alkyl- oder Arylsulfonat-Anionen oder Alkyl- oder Arylcarboxylat-Anionen durch Umsetzung eines Onium-Halogenids mit einem Alkyl- oder Trialkylsilylester einer Alkyl- oder Arylsulfonsäure oder einer Alkyl- oder Arylcarbonsäure oder deren Anhydride.

Подробнее
09-01-1991 дата публикации

RECOVERY OF PRECIOUS METALS

Номер: GB0002186563B
Принадлежит: HENKEL CORP, * HENKEL CORPORATION

Подробнее
14-08-1994 дата публикации

New peptides derivatives.

Номер: AP0000000353A
Принадлежит:

The invention relates to new competitive inhibitors of ...

Подробнее
31-01-1993 дата публикации

NEW PEPTIDES DERIVATIVES

Номер: AP0009200457A0
Автор:
Принадлежит:

Подробнее
31-08-2007 дата публикации

Peptidic compounds

Номер: AP2007004093A0
Принадлежит:

Подробнее
18-03-2013 дата публикации

Peptidic compounds

Номер: AP0000002616A
Принадлежит:

Подробнее
31-01-1993 дата публикации

NEW PEPTIDES DERIVATIVES

Номер: AP0009200457D0
Автор:
Принадлежит:

Подробнее
12-09-1977 дата публикации

MIKROBIZIDES MEANS

Номер: AT0000338564B
Автор:
Принадлежит:

Подробнее
16-07-2020 дата публикации

COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS

Номер: AU2018279007B2
Принадлежит: Phillips Ormonde Fitzpatrick

A compound of the formula: R3 |L 1. o 5 or a pharmaceutically acceptable salt thereof, wherein: L is selected from the group consisting of -CH20-, -CH2CH20-, -NHCH 2-, -CH2NH-, NHCH 2CH2-, -CH2CH2NH-, -CH2CH2CH2-, -CH=N-, -N=CH-, and R is selected from the group consisting of: NRB J NRB B N N :o NRB k-, N NRB N(RH)2 NH and H 15 wherein each occurrence of RB is independently hydrogen, substituted or unsubstituted C1 . 0 alkyl, or a nitrogen-protecting group, provided at least two RB are hydrogen; R2 and R 6 are hydrogen; each of R3, R4 and R 5 is independently hydrogen, halogen, substituted or unsubstituted C1 .10 alkyl, substituted or unsubstituted C2 -1 0 alkoxyalkyl, substituted or unsubstituted C 3 .14 20 aryl, -ORAl, -N(RA2 )2 , or -CN; and each occurrence of R andRA2 is independently hydrogen, substituted or unsubstituted C1.10 alkyl, or substituted or unsubstituted C3.14 aryl; provided at least one imaging moiety is present in the compound, wherein the imaging moiety is 18F.

Подробнее
10-07-2014 дата публикации

Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction

Номер: AU2012335981A1
Принадлежит:

The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.

Подробнее
03-12-2020 дата публикации

Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction

Номер: AU2012335981C1
Принадлежит: Davies Collison Cave Pty Ltd

The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.

Подробнее
20-11-1997 дата публикации

Synthesis of a serine protease inhibitor

Номер: AU0000683793B2
Принадлежит:

Подробнее
05-10-2010 дата публикации

BICYCLIC GUANIDINE DERIVATIVES AND THERAPEUTIC USES THEREOF

Номер: CA0002441331C

The invention relates to compounds of general formula (I), in which A, X, Y and R1 are defined in Claim 1. These compounds may be used in the treatment of pathologies associated with insulin resistane syndrome.

Подробнее
24-03-2011 дата публикации

PRODRUGS OF GUANFACINE

Номер: CA0002774147A1
Принадлежит:

Prodrugs of guanfacine with amino acids or short peptides,pharmaceutical compositions containing such prodrugs and a method for providing therapeutic benefit in the treatment of ADHD/ODD (attention deficient hyperactivity disorder and oppositional defiance disorder) with guanfacine prodrugs are provided herein. Additionally, methods for minimizing or avoiding the adverse gastrointestinal side effects associated with guanfacine administration, as well as improving the pharmacokinetics of guanfacine are provided herein.

Подробнее
19-07-2018 дата публикации

HYDROTROPIC COMPOSITION AND ITS USES

Номер: CA0003048369A1
Принадлежит: ROBIC

Hydrotropic composition comprising at least one surface active cationic component, which is selected from a group of cholinium, guadinium or tetramethylguadinium, preferably cholinium, and a straight or branched carboxylate anion having at least six carbon atoms; and its uses, for treating of oil sands or the like, for treating tailings from separation of bitumen, asphaltenes or the like.

Подробнее
24-08-2006 дата публикации

COMPOUNDS AND USES THEREOF

Номер: CA0002597306A1
Принадлежит:

Подробнее
28-01-2010 дата публикации

MIXTURES OF AMINES WITH GUANIDINE DERIVATIVES

Номер: CA0002730518A1
Принадлежит:

The present invention relates to a mixture containing at least three hardener components a1), a2), and b), wherein the ratio of the hardener component a1) to a2) is in the range of 0.1-10 to 1, and the hardener component b) is present with 5 to 55 weight percent, relative to the mixture, to a method for producing said mixture, to the use of the mixture according to the invention for hardening epoxy resins, to the use of the mixture according to the invention having epoxy resins as adhesives, and to an epoxy resin hardened with the mixture according to the invention.

Подробнее
27-09-2016 дата публикации

BLENDS COMPRISING EPOXY RESINS AND MIXTURES OF AMINES WITH GUANIDINE DERIVATIVES

Номер: CA0002729895C
Принадлежит: BASF SE

The present invention relates to a blend containing one or more epoxy resins and a mixture, which contains 0.3 to 0.9 amine equivalent per epoxy equivalent of the epoxy resin used of a hardening component a) and a compound of the formula I as a hardening component b), to a method for producing said blend, to the use of the blend according to the invention for producing hardened epoxy resin, and to an epoxy resin hardened with the blend according to the invention.

Подробнее
15-11-1976 дата публикации

Номер: CH0000581433A5
Автор:
Принадлежит: CIBA GEIGY AG, CIBA-GEIGY AG

Подробнее
30-05-1984 дата публикации

Aminoalkylbenzene derivatives having a selective action on histamine receptors

Номер: CH0000643238A5
Принадлежит: ALLEN & HANBURYS LTD, ALLEN & HANBURYS LTD.

The invention provides aminoalkylbenzene derivatives of the general formula in which R1 and R2, which may be identical or different, represent hydrogen or lower alkyl, cycloalkyl, aralkyl or lower alkenyl groups, or lower alkyl groups which are interrupted by an oxygen atom or a group in which R4 has the meaning hydrogen or lower alkyl, or R1 and R2 form, together with the nitrogen atom to which they are attached, a heterocyclic rings which may contain the hetero functions -O- and , R3 represents hydrogen, lower alkyl, alkenyl or alkoxyalkyl, X represents -O-, -S-, -CH2- or in which R5 has the meaning hydrogen or lower alkyl, Y represents =S, =O, =NR6 or =CHR7, where R6 has the meaning hydrogen, nitro, cyano, lower alkyl, aryl, arylsulphonyl or lower alkylsulphonyl, R7 represents nitro, lower alkylsulphonyl or arylsulphonyl, m is an integer from 2 to 4, n has the value 0, 1 or 2 and Alk represents a straight-chain or branched alkylene chain having from 1 to ...

Подробнее
03-01-2001 дата публикации

9,10-Dihydro-9,10-ethanoanthracene derivatives as phospholipase inhibitors

Номер: CN0001278789A
Принадлежит:

Подробнее
30-07-2004 дата публикации

DERIVED BICYCLIQUES FROM GUANIDINES AND THEIR APPLICATIONS INTO THERAPEUTIC

Номер: FR0002822463B1
Автор: MOINET, CRAVO
Принадлежит: LIPHA

Подробнее
09-05-2008 дата публикации

COMPOSITION OF DEFRISAGE OF THE HAIR INCLUDING/UNDERSTANDING AT LEAST A MULTIGUANIDINE EXCEPT HYDROXIDE

Номер: FR0002885902B1
Автор: MALLE, BLAISE, RADISSON
Принадлежит: L'OREAL

Подробнее
06-06-1975 дата публикации

Zinc ethylene bis-dithiocarbamate-n-dodecylguanidine double - salts preps - fungicides

Номер: FR0002121351B1
Автор:
Принадлежит:

Подробнее
27-09-2002 дата публикации

New N-bicyclo-substituted methyl-guanidine derivatives, useful for treating insulin-resistance syndrome and associated conditions

Номер: FR0002822463A1
Принадлежит:

L'invention concerne des composés de formule générale (I) : dans laquelle A, X, Y et RI sont tels que définis dans la revendication 1. Ces composés sont utilisables dans le traitement des pathologies associées au syndrome d'insulinorésistance.

Подробнее
26-10-2018 дата публикации

염미 증강제 및 그 제조 방법, 그리고 염미 증강 방법

Номер: KR0101912494B1

... 본원은 신규의 염미 증강제 및 그 제조 방법, 그리고 음식품의 염미 증강 방법을 제공하는 것을 과제로 한다. 이러한 과제를 해결하는 수단으로서, 하기 일반식 (1) 로 나타내는 화합물 또는 그 염으로 이루어지는 염미 증강제를 제공한다. [식 중, R 은 명세서에 정의되는 바와 같다] ...

Подробнее
01-05-2010 дата публикации

Process for preparing moldings using mixtures of amines with guanidine derivatives

Номер: TW0201016744A
Принадлежит:

The present invention provides a process for producing moldings, the curing of the mold being carried out using a blend comprising one or more epoxy resins and a mixture, the curing component (a) being used within the mixture in the range from 0.3 to 0.9 amine equivalent per equivalent of epoxide of the epoxy resin used, and the hardener component (b) being a compound of the formula I.

Подробнее
04-02-1999 дата публикации

NOVEL COMPOSITIONS FOR THE DELIVERY OF NEGATIVELY CHARGED MOLECULES

Номер: WO1999005094A1
Принадлежит:

This invention features permeability enhancer molecules, and methods, to increase membrane permeability of negatively charged polymers thereby facilitating cellular uptake of such polymers.

Подробнее
15-09-1992 дата публикации

Cyclophanes, pharmaceutical compositions containing these compounds and processes for preparing them

Номер: US0005147882A1
Принадлежит: Karl Thomae GmbH

Cyclophanes of the general formula см. иллюстрацию в PDF-документе wherein X1, X2, A, R and R1 to R4 are as defined herein, the enantiomers, diastereomers and addition salts thereof and, more particularly, for pharmaceutical use, the physiologically acceptable addition salts thereof, which have pharmacological properties such as lowering blood pressure, dilating the coronary blood vessels and a mild heart rate lowering activity, pharmaceutical compositions which contain these compounds and processes for preparing them.

Подробнее
23-03-2017 дата публикации

AMIDINE GROUP - OR GUANIDINE GROUP - CONTAINING SILANE

Номер: US20170081348A1
Принадлежит: SIKA TECHNOLOGY AG

A silane of the formula (I) containing at least one aliphatic amidine group- or guanidine group-containing alkoxy group, to a method for producing same, to conversion products thereof, and to the use thereof as a catalyst in curable compositions, in particular based on silane group-containing polymers. The silane of the formula (I) is largely odorless and non-volatile at room temperature. The silane accelerates the hydrolysis and condensation reaction of silane groups very effectively without impairing the storage stability of silane group-containing polymers. Additionally, the silane is very tolerable in silane group-containing compositions, whereby such compositions are not prone to separate, migrate, or evaporate the catalyst.

Подробнее
09-03-2005 дата публикации

Novel adamantane derivatives with neuroprotective, antidepressant and anti-ischaemic activities, and process for preparing them

Номер: EP0001512679A1
Принадлежит:

The invention describes compounds represented by the general formula (I) given below: in which: n is an integer between 1 and 4; R1 and R2 are chosen independently from hydrogen and a methyl group; R3 is chosen independently from a linear, branched or cyclic alkyl group containing from 1 to 3 carbon atoms (R3a) and a simple amino group (R3b) or an amino group substituted with a nitro group (R3c). The compounds are useful for treating central nervous system diseases or peripheral neuropathies.

Подробнее
19-07-2000 дата публикации

NOVEL COMPOSITIONS FOR THE DELIVERY OF NEGATIVELY CHARGED MOLECULES

Номер: EP0001019365A1
Принадлежит: Ribozyme Pharmaceuticals Inc

This invention features permeability enhancer molecules, and methods, to increase membrane permeability of negatively charged polymers thereby facilitating cellular uptake of such polymers.

Подробнее
10-12-2016 дата публикации

СРЕДСТВО, УСИЛИВАЮЩЕЕ СОЛЕНЫЙ ВКУС, И СПОСОБ ИЗГОТОВЛЕНИЯ, И СПОСОБ УСИЛЕНИЯ СОЛЕНОГО ВКУСА

Номер: RU2015118383A
Принадлежит:

... 1. Средство, усиливающее соленый вкус, включающее соединение, представленное следующей общей формулой (1), или его соль:где R представляет собой:(i) линейную или разветвленную углеводородную группу, имеющую 1-5 атомов углерода, которые могут прерываться гетероатомом, где углеводородная группа может иметь, по меньшей мере, одну группу, выбранную из группы, состоящей из карбоксильной группы и гидроксильной группы; или(ii) атом водорода.2. Средство, усиливающее соленый вкус, по п. 1, где соединение, представленное общей формулой (1), или его соль включает соединение, представленное любой из приведенных ниже общих формул (2)-(6), или его соль:,,,,,где Q представляет собой гетероатом, и q представляет собой 0 или 1;m и n, каждый из них, представляют собой целое число от 1 до 4, и m+n представляет собой целое число от 3 до 5;m′ и n′, каждый из них, представляют собой целое число от 1 до 3, и m′+n′ представляет собой целое число от 2 до 4; иk представляет собой целое число от 0 до 3.3. Средство ...

Подробнее
30-07-1993 дата публикации

METHOD OF EXTRACTION OF NOBLE METALS FROM ALKALINE CYAN SOLUTIONS

Номер: RU1831508C
Принадлежит: Хенкель Корпорейшн

Использование: касаетс  извлечени  благородных металлов из цианистых растворов сорбцией или экстракцией. Восстановление благородных металлов, например золота и серебра, из их водных цианистых растворов, содержащих функциональную группу гуанидина. Регант гуани- дин извлекает благородный металл из водного раствора, который затем отдел ют от реагента гуанидина и восстанавливают обычными способами. Раскрыты новые соединени  гуанидина дл  извлечени  золота и серебра. 3 з.п.ф-лы.

Подробнее
22-06-1977 дата публикации

ISONICOTINIC ACID DERIVATIVES

Номер: GB0001477230A
Автор:
Принадлежит:

... 1477230 Isonicotinic acid derivatives CIBAGEIGY AG 16 Dec 1974 [17 Dec 1973] 54288/74 Heading C2C The invention comprises compounds of Formula (I) wherein X represents chlorine, bromine or iodine, R 1 represents a C 1 -C 12 -alkyl group optionally substituted by hydroxy, C 1 -C 4 - alkoxy, amino or mono- or di-C 1 -C 2 -alkylamino, or a C 3 -C 4 -alkenyl group, C 3 -C 8 -oycloalkyl group, benzyl group, p-acetylbenzyl group or phenethyl group, and R 2 represents hydrogen or a C 1 -C 4 -alkyl group or a C 3 -C 4 - alkenyl group, or R 1 and R 2 together with the nitrogen atom to which they are attached represent a 5- to 7-membered heterocyclic group, which optionally can additionally contain an oxygen atom; and their salts with organic and inorganic bases. The compounds of Formula (I) may be prepared by reacting a compound of formula with an amine of formula The compounds of Formula (I) are used in compositions for the control of phytopathogenic bacteria.

Подробнее
15-03-2000 дата публикации

NEW PEPTIDDERIVATE

Номер: AT0000190066T
Принадлежит:

Подробнее
15-12-1976 дата публикации

MIKROBIZIDES MITTEL

Номер: ATA1000474A
Автор:
Принадлежит:

Подробнее
15-12-1976 дата публикации

MIKROBIZIDES MEANS

Номер: AT0001000474A
Автор:
Принадлежит:

Подробнее
20-05-2021 дата публикации

New ammonium salts of fluorinated organic acids, method of their synthesis and application

Номер: AU2019367331A1
Принадлежит:

The present invention relates to ammonium salts of partially fluorinated organic acids, represented by the general formula 1. The present invention relates also to a synthesis method of said salts as well as its use to the production of stable emulsions oil-in-water and/or water-in-oil type, as stabilising agent in blood substitute preparations.

Подробнее
17-08-2017 дата публикации

Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction

Номер: AU2012335981B2
Принадлежит: Davies Collison Cave Pty Ltd

The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.

Подробнее
02-01-1991 дата публикации

SALTS OF AMINO-BETA-LACTAMIC ACIDS AND PROCESS FOR THE PREPARATION THEREOF

Номер: CA0001278568C
Принадлежит: GEMA SA, GEMA, S.A.

Amino-beta-lactamic acid salts, having the formula: (I) wherein: (X-Y) may form a system having from 1 to 3 carbon atoms, with or without double bond, a) closed, in which: X is an atom selected from among carbon, oxygen, nitrogen and sulphur; Y is methylene; z is carboxy (-COO), b) open, which may comprise a double bond, in which: X is an atom of hydrogen or a methyl, hydroxymethyl or thiol group, Y is an acid radical chosen from the group formed by sulphonic (-SO3), phosphonic (-PO3H) or sulphoamidic (-SO2NH2) acid; Z is missing. R is an atom or hydrogen, or a methoxyl or ethoxyl group. R1 is, when present, methyl, acetoxymethyl, acylthiomethyl, such as acetyl and benzoyl derivatives, methoxy, chlorine, carbamoyloxymethyl, azido, azidomethyl (alpha, beta)-thioethylamine or a thiomethyl-heterocyclic derivative of the thiazole, thiadiazole, triazole, tetrazole, oxazole, oxadiazole, pyrimidine and imidazole nuclei. R2 is an atom of hydrogen or a methyl, ethyl, benzyl or aryl group.

Подробнее
27-09-2016 дата публикации

MIXTURES OF AMINES WITH GUANIDINE DERIVATIVES

Номер: CA0002730518C
Принадлежит: BASF SE

The present invention relates to a mixture containing at least three hardener components a1), a2), and b), wherein the ratio of the hardener component a1) to a2) is in the range of 0.1-10 to 1, and the hardener component b) is present with 5 to 55 weight percent, relative to the mixture, to a method for producing said mixture, to the use of the mixture according to the inventi-on for hardening epoxy resins, to the use of the mixture according to the invention having epoxy resins as adhesives, and to an epoxy resin hardened with the mixture according to the invention.

Подробнее
10-06-1993 дата публикации

NEW PEPTIDE DERIVATIVES

Номер: CA0002125175A1
Принадлежит:

... 2125175 9311152 PCTABS00022 The invention relates to new competitive inhibitors of thrombin, their synthesis, pharmaceutical compositions containing the compounds as active ingredients, and the use of the compounds as anticoagulants for prophylaxis and treatment of thromboembolic diseases, according to formula (I) wherein A represents a methylene group, an ethylene group or a propylene group, which may be substituted or A represents -CH2-O-CH2-, -CH2-S-CH2-, -CH2-SO-CH2-, or A represents -CH2-O-, -CH2-S-, -CH2-SO-, with the heteroatom functionality in position 4, or n is an integer 2 to 6; and B represents -N(R6)-C(NH)-NH2, wherein R6 is H or a methyl group, or B represents -S-C(NH)-NH2, or -C(NH)-NH2. Further described is new use in synthesis of pharmaceutical compounds of a compound of formula (II).

Подробнее
30-12-2013 дата публикации

HYPOLIPIDEMIC ANTIDIABETIC AGENT

Номер: EA0201391028A1
Автор:
Принадлежит:

Подробнее
05-07-1985 дата публикации

DERIVED From the DECRAPENYLAMINE, THEIR ACID SALTS Of ADDITION AND PHARMACEUTICAL COMPOSITION CONTAINING THESE PRODUCTS

Номер: FR0002470110B1
Автор:
Принадлежит:

Подробнее
16-10-2015 дата публикации

Borate base generator and base reactive composition containing the same

Номер: TW0201538512A
Принадлежит: Wako Pure Chem Ind Ltd

本發明之課題是提供一種化合物、包含該等化合物的鹼產生劑以及含有該鹼產生劑與鹼反應性化合物之鹼反應性組成物,該化合物係在與環氧系化合物等的鹼反應性化合物混合的狀態長期間保存時,也不會與該鹼反應性化合物反應,可成為保存安定性高的組成物,並且,可由光(活性能量射線)的照射或加熱而產生強鹼(胍類、雙胍類、膦氮烯類或鏻類)的化合物。 本發明係關於通式(A)所示之化合物,包含該化合物的鹼產生劑,以及其特徵係含有該鹼產生劑及鹼反應性化合物的鹼反應性組成物等。 □(式中,R1表示烷基;可經鹵原子、烷基、烷氧基、或烷硫基取代的芳炔基;烯基;2-呋喃基乙炔基;2-硫苯基乙炔基;或2,6-二噻環己基(2,6-dithianyl),R2至R4各自獨 立地表示烷基;可經鹵原子、烷基、烷氧基、或烷硫基取代的芳炔基;可經鹵原子、烷基、烷氧基、或烷硫基取代的芳基;呋喃基;噻吩基;或N-烷基取代吡咯基,Z+表示具有胍鎓基、雙胍鎓基或膦氮烯鎓基的銨陽離子,或鏻陽離子。)

Подробнее
07-12-1994 дата публикации

PEPTIDE DERIVATIVES

Номер: SK0000063194A3
Автор:
Принадлежит:

Подробнее
20-01-2011 дата публикации

N-PHOSPHONOMETHYLGLYCINE GUANIDINE DERIVATIVE SALTS

Номер: WO2011008453A8
Принадлежит:

The present invention provides N-phosphonomethylglycine guanidine salts. The N-phosphonomethylglycine guanidine salts have improved herbicidal efficacy over glyphosate alone. The present invention also provides guanidine compounds and salts thereof.

Подробнее
10-06-1993 дата публикации

NEW PEPTIDE DERIVATIVES

Номер: WO1993011152A1
Принадлежит:

The invention relates to new competitive inhibitors of thrombin, their synthesis, pharmaceutical compositions containing the compounds as active ingredients, and the use of the compounds as anticoagulants for prophylaxis and treatment of thromboembolic diseases, according to formula (I) wherein A represents a methylene group, an ethylene group or a propylene group, which may be substituted or A represents -CH2-O-CH2-, -CH2-S-CH2-, -CH2-SO-CH2-, or A represents -CH2-O-, -CH2-S-, -CH2-SO-, with the heteroatom functionality in position 4, or n is an integer 2 to 6; and B represents -N(R6)-C(NH)-NH2, wherein R6 is H or a methyl group, or B represents -S-C(NH)-NH2, or -C(NH)-NH2. Further described is new use in synthesis of pharmaceutical compounds of a compound of formula (II).

Подробнее
25-01-1994 дата публикации

Fungicidal guanidines

Номер: US0005281625A1
Принадлежит: BASF Aktiengesellschaft

Guanidines I см. иллюстрацию в PDF-документе (A=C5 -C12 -cycloalkyl which may bear up to three further substituents; benzyl substituted in the para-position; R1, R2, R3 =H, C1 -C4 -alkyl; R4 =C5 -C18 -alkyl which may be interrupted by oxygen, C5 -C18 -alkenyl, C4 -C18 -alkynyl or phenyl-C1 -C6 -alkyl, and these groups may bear up to three further substituents and the phenyl moiety of the phenylalkyl may additionally bear a phenoxy group or up to three C2 -C4 -alkenyl, C1 -C4 -alkoxy-C1 -C4 -alkyl, C1 -C6 -alkyl or haloalkyl groups, C5 -C6 -cycloalkyl-C1 -C8 -alkyl, where the ring may bear up to three further substituents; A=benzyl and R4 =C3 -C4 -alkyl which may be interrupted by oxygen, or C4 -alkenyl, both of which may bear up to three further substituents; R3 +R4 =C5 -C6 -heterocycle which may bear up to three further substituents and may be interrupted by oxygen) and the salts I.HX and the metal complexes of I. The compounds I are suitable as fungicides.

Подробнее
28-11-2019 дата публикации

ANTI-INFLAMMATORY DRUG AND USES THEREOF

Номер: US2019359560A1
Принадлежит:

An anti-inflammatory drug containing a G0/G1 switch 2 (G0S2) inhibitor as an active ingredient is useful as a novel anti-inflammatory drug.

Подробнее
24-04-2023 дата публикации

Способ синтеза новых водорастворимых сополимеров гуанидинового ряда

Номер: RU2794663C1
Автор:

Изобретение относится к способу синтеза модифицированного гуанидинсодержащего сополимера, используемого для создания антибактериальных препаратов широкого спектра действия на его основе. Способ осуществляют методом поликонденсации в расплаве 1,6-диаминогексана (ГМДА), 1,8-диаминооктана (ОМДА) и гуанидин гидрохлорида (ГГХ) при мольных соотношениях ГМДА:ОМДА:ГГХ, выбранных из 0,9:0,1:1; 0,75:0,25:1; 0,5:0,5:1 при ступенчатом повышении температуры до 165°С в течение 6 часов. Технический результат – синтез модифицированных водорастворимых сополимеров полигуанидина с улучшенными антибактериальными свойствами путем варьирования гидрофобно-гидрофильного баланса макромолекулы при одновременном использовании двух различных аминов. 1 ил., 3 пр.

Подробнее
06-09-1979 дата публикации

Номер: DE0002647915B2
Принадлежит: KEMANORD AB, STOCKHOLM

Подробнее
05-03-2003 дата публикации

Guanidinium and isothiouronium compounds and methods for their use

Номер: GB0002379219A
Принадлежит:

Anti-fouling agents comprising isothiouronium salts, guanidinium salts, and their conjugate base analogs are provided. Anti-fouling coating compositions that include these anti-fouling agents are also provided. Such anti-fouling agents and coating compositions are useful for inhibiting the fouling by microorganisms and higher organisms of surfaces exposed to humid conditions or submerged in water.

Подробнее
16-02-2012 дата публикации

Polyamines useful as anti-parasitic and anti-cancer therapeutics and as lysine-specific demethylase inhibitors

Номер: AU2006279943B2
Принадлежит:

Polyamine, polyamine/guanidino, and polyamine/biguanide compounds are disclosed. The compounds are useful as anti-cancer and anti-parasitic treatments. The compounds are also useful as inhibitors of the enzyme lysine-specific demethylase-1.

Подробнее
13-10-1994 дата публикации

Substituted guanidines having high binding to the sigma receptor and the use thereof

Номер: AU0000653729B2
Принадлежит:

Подробнее
01-08-1996 дата публикации

Synthesis of a serine protease inhibitor

Номер: AU0005061696A
Принадлежит:

Подробнее
04-11-1988 дата публикации

METHOD FOR THE PREPARATION OF AMIDINO-UREA DERIVATIVES

Номер: AU0001598088A
Принадлежит:

Подробнее
25-10-2001 дата публикации

GUANIDINIUM AND ISOTHIOURONIUM COMPOUNDS AND METHODS FOR THEIR USE

Номер: CA0002408386A1
Принадлежит:

Anti-fouling agents comprising isothiouronium salts, guanidinium salts, and their conjugate base analogs are provided. Anti-fouling coating compositions that include these anti-fouling agents are also provided. Such anti-fouling agents and coating compositions are useful for inhibiting the fouling by microorganisms and higher organisms of surfaces exposed to humid conditions or submerged in water.

Подробнее
21-01-1986 дата публикации

SPERGUALIN-RELATED COMPOUNDS AND PROCESS FOR PRODUCTION THEREOF

Номер: CA1199641A
Принадлежит: MICROBIAL CHEM RES FOUND

This invention relates to novel spergualin-related compounds and to a process for the production thereof. The novel compounds, which have a high antitumor activity, are represented by the general formula < IMG > (I) wherein R1 represents a hydrogen atom, hydroxyl group, or an alipllatic acyloxy group having 1 to 10 carbon atoms. R2 represents the residue of an .alpha.,.omega.-amino acid, other than a residue of .alpha.-hydroxyglycine, linked by acid amide groups to the adjacent carbonyl and amino groups, and m is 4, 5, or 6.

Подробнее
30-04-2020 дата публикации

NEW AMMONIUM SALTS OF FLUORINATED ORGANIC ACIDS, METHOD OF THEIR SYNTHESIS AND APPLICATION

Номер: CA3117605A1
Принадлежит:

The present invention relates to ammonium salts of partially fluorinated organic acids, represented by the general formula 1. The present invention relates also to a synthesis method of said salts as well as its use to the production of stable emulsions oil-in-water and/or water-in-oil type, as stabilising agent in blood substitute preparations.

Подробнее
21-01-1992 дата публикации

SPERGUALIN-RELATED COMPOUND AND USE THEREOF

Номер: CA0002047341A1
Принадлежит:

Novel spergualin-related compounds represented by the general formula (I): (I) wherein X represents -(CH2)1-5- or a phenylene group which may be substituted; m represents 0, 1 or 2; n represents 1 or 2; and R1 represents -(CH2)1-3-COOH, and pharmacologically acceptable salts thereof, possess an immunopotentiating activity, and are expected to be useful as immunopotetiators applicable to warm blooded animals.

Подробнее
27-07-1999 дата публикации

IMPROVEMENTS IN AND RELATING TO GUANIDINE DERIVATIVES

Номер: CA0002009074C
Принадлежит:

This invention provides the compound (-)-N"-cyano-N-3-pyridyl-N'-1,2,2-trimethylpropylguanidine, its salts and pharmaceutical formulations, and its method of use for opening potassium channels in mammals. The above compound is the (-) isomer of a compound of the structural formula: (see fig. I) ...

Подробнее
03-08-1990 дата публикации

GUANIDINE DERIVATIVES

Номер: CA0002009074A1
Принадлежит:

Подробнее
25-10-1985 дата публикации

NEW GUANIDINES HAVE STRONG STERIC OBSTRUCTION AND PROCESSES FOR THEIR PREPARATION

Номер: FR0002509724B1
Автор: [UNK]

Подробнее
27-04-2017 дата публикации

HEPSIN INHIBITOR FOR PREVENTING AND TREATING METASTASIS OF PROSTATE CANCER AND PHARMACEUTICAL COMPOSITION COMPRISING SAME

Номер: KR1020170045574A
Автор: BYUN, YOUNG JOO
Принадлежит:

The present invention relates to a compound derivative controlling functions of hepsin, which is over-expressed in metastatic prostate cancer, and to a pharmaceutical composition for preventing or treating metastatic prostate cancer comprising the same and, more specifically, to a compound derivative represented by chemical formula 1 and a pharmaceutical composition for preventing or treating metastatic prostate cancer comprising the same. COPYRIGHT KIPO 2017 ...

Подробнее
18-06-2013 дата публикации

BIGUANIDE DERIVATIVES, METHODS OF PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

Номер: KR0101274981B1
Принадлежит: 한올바이오파마주식회사

본 발명은 N1-N5-치환된 하기 화학식 1로 표시되는 바이구아나이드 유도체 또는 그의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 유효성분으로 약학 조성물을 제공한다. 본 발명의 바이구아나이드 유도체는 기존 약물에 비해 적은 양으로도 우수한 AMPKα 활성화 효과 및 암세포 증식 억제 효과를 나타내어 당뇨, 비만, 고지혈증, 고콜레스테롤혈증, 지방간, 관상동맥질환, 골다공증, 다낭성 난소증후군, 대사성 증후군, 암 등의 치료를 위해 유용하게 이용될 수 있다. [화학식 1] The present invention provides a pharmaceutical composition as an N1-N5-substituted biguanide derivative represented by the following Chemical Formula 1 or a pharmaceutically acceptable salt thereof, a preparation method thereof, and an active ingredient thereof. The biguanide derivative of the present invention exhibits excellent AMPKα activation effect and cancer cell proliferation inhibitory effect even in a small amount compared to conventional drugs, such as diabetes, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome, and metabolic activity. It can be usefully used for the treatment of syndrome, cancer and the like. [Formula 1]

Подробнее
12-04-2011 дата публикации

poliaminas úteis como produtos terapêuticos antiparasìticos e anticáncer e como inibidores de demetilase lisina-especìficos

Номер: BRPI0614805A2
Автор:
Принадлежит:

Подробнее
01-10-2009 дата публикации

COMPOUNDS HAVING A GUANIDINE STRUCTURE AND USE OF SAME AS ORGANOPOLYSILOXANE POLYCONDENSATION CATALYSTS

Номер: WO000002009118307A3
Принадлежит:

The invention relates to novel compounds having a guanidine structure and to the use of same as organopolysiloxane polycondensation catalysts.

Подробнее
29-12-2011 дата публикации

ANTIMICROBIAL AGENTS

Номер: WO2011163610A3
Принадлежит:

The invention provides a compound of formula I:or a salt thereof, wherein R3-R8 and X and Y have any of the values described in the specification, as well as compositions comprising a compound of formula I. The compounds are useful as antibacterial agents.

Подробнее
24-07-2002 дата публикации

Номер: JP0003306826B2
Автор:
Принадлежит:

Подробнее
20-06-1998 дата публикации

АНАЛОГИ 15-ДЕЗОКСИСПЕРГУАЛИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ, СПОСОБ ПОЛУЧЕНИЯ ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ (ВАРИАНТЫ), АМИНОЗАЩИЩЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ АНАЛОГОВ 15-ДЕЗОКСИСПЕРГУАЛИНА

Номер: RU2113431C1

FIELD: organic chemistry; medicine. SUBSTANCE: novel commercial products having structure which is analog to those of 15-desoxypergyaline with formula I (where A is single bond, -CH 2 - group, -CH 2 O- group, -CH 2 NH- group, CH(OH)- group, CHF- group or -OH(OCH 3 ) group; n is 6 or 8) and additive salts thereof are proposed. Compounds having formula I are prepared of compounds having formula II тс ГЬсС ПЫ Го РОССИЙСКОЕ АГЕНТСТВО ПО ПАТЕНТАМ И ТОВАРНЫМ ЗНАКАМ (19) (51) МПК ВИ” 2113 431. 13) СЛ С 07С 279/22, 277/00, Аб1 К 31/175 12) ОПИСАНИЕ ИЗОБРЕТЕНИЯ К ПАТЕНТУ РОССИЙСКОЙ ФЕДЕРАЦИИ (21), (22) Заявка: 95102479/04, 23.02.1995 (30) Приоритет: 24.02.1994 ЕКВ 94 02125 01.06.1994 ЕВ 94 06706 (46) Дата публикации: 20.06.1998 (56) Ссылки: ЕР 0181592, кл. С 07 С 279/104, 1986. ЕР 0105193, кл. С 07 С 12912, 1983. (71) Заявитель: Фурнье Эндюстри э Санте (ЕК) (72) Изобретатель: Патрис Рено (ЕК), Люк Лебретон (ЕК), Патрик Дютартр (ЕК), Филипп Деррепа (ЕК), Сот Самрет (ЕК) (73) Патентообладатель: Фурнье Эндюстри э Санте (ЕК) (54) АНАЛОГИ 15-ДЕЗОКСИСПЕРГУАЛИНА, СПОСОБ ИХ ПОЛУЧЕНИЯ, СПОСОБ ПОЛУЧЕНИЯ ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИЙ (ВАРИАНТЫ), АМИНОЗАЩИЩЕННЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ПРОМЕЖУТОЧНЫХ СОЕДИНЕНИИ И ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ АНАЛОГОВ 15-ДЕЗОКСИСПЕРГУАЛИНА (57) Реферат: Изобретение относится в качестве новых промышленных продуктов к соединениям структуры, аналогичной таковой 15-дезоксиспергуалина, формулы | МН>С(= МНУМН(СН2)- - МНС(= ОЗАС(= О)МН(СН 2МНСНЯСН(СНЭМНо (9 ВАМНС( МВ.)МН(СН2).МНС(= 0) АС( ОУМН(МН 2)4МН(СН>)2СН(СНзМНВ (1, в которой А обозначает простую связь, группу-СН>-, группу -СН5О, группу - СНЫМН, группу-СН(ОН)-, группу - СНЁЕ- или группу -ОН(ОСНЗ); и п равно 6 или 8, и их солям присоединения. Эти новые соединения особенно пригодны В качестве иммунодепрессивных агентов. Изобретение также относится к способу получения вышеуказанных соединений | удалением защитных групп из соединений формулы 1. Способ получения соединений формулы 1 конденсацией кислоты с ...

Подробнее
07-06-2012 дата публикации

Compositions and methods relating to proliferative diseases

Номер: US20120141578A1
Принадлежит: PENN STATE RESEARCH FOUNDATION

Anti-cancer compositions and methods are described herein. In particular, compositions including one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described. Methods for treatment of pathological conditions particularly cancer, in a subject using one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described herein.

Подробнее
25-04-2013 дата публикации

Curable polysiloxane coating composition

Номер: US20130101840A1
Принадлежит: 3M Innovative Properties Co

A curable composition comprises (a) at least one polydiorganosiloxane, fluorinated polydiorganosiloxane, or combination thereof comprising reactive silane functionality comprising at least two hydroxysilyl moieties; (b) at least one polydiorganosiloxane, fluorinated polydiorganosiloxane, or combination thereof comprising reactive silane functionality comprising at least two hydrosilyl moieties; and (c) at least one base selected from amidines, guanidines, phosphazenes, proazaphosphatranes, and combinations thereof; wherein at least one of the components (a) and (b) has an average reactive silane functionality of at least three.

Подробнее
08-01-2015 дата публикации

ANTIMICROBIAL AGENTS

Номер: US20150011559A1
Принадлежит:

The invention provides methods of treating a bacterial infection in a mammal comprising administering to the mammal a compound of formula I: 2. The method of wherein ring A is phenyl claim 1 , which is substituted with one or more Rand which is optionally substituted with one or more R.3. The method of wherein ring A is thiazolyl claim 1 , which is substituted with one or more Rand which is optionally substituted with one or more R.4. The method of wherein Ris methyl claim 1 , phenyl claim 1 , tert-butyl claim 1 , bromo claim 1 , cyclohexyl claim 1 , thiazolyl claim 1 , biphenyl claim 1 , thiazol-2-ylaminocarbonyl claim 1 , or cyclopropyl.5. The method of wherein B is phenyl substituted with one or more Rand optionally substituted with one or more R.6. The method of wherein B is pyridyl substituted with one or more Rand optionally substituted with one or more R.7. The method of wherein B is thiazolyl substituted with one or more Rand optionally substituted with one or more R.9. The method of wherein each Ris selected from methoxy claim 1 , methyl claim 1 , N claim 1 ,N-dimethylaminomethyl claim 1 , bromo claim 1 , 4-tert-butylphenyl claim 1 , 4-trifluoromethoxy-2-methoxyphenyl claim 1 , nitro claim 1 , amino claim 1 , methylsulfonylamino claim 1 , methylcarbonylamino claim 1 , hydroxymethyl claim 1 , 2-(N claim 1 ,N-diethylamino)ethylaminocarbonyl claim 1 , methoxy claim 1 , —(OCHCH)—OCH claim 1 , 2 claim 1 ,2-dibromoethyl claim 1 , thiazol-2-ylaminocarbonyl claim 1 , and methoxycarbonyl.10. The method of wherein each Ris selected from methoxy claim 1 , N claim 1 ,N-dimethylaminomethyl claim 1 , bromo claim 1 , 4-tert-butylphenyl claim 1 , 4-trifluoromethoxy-2-methoxyphenyl claim 1 , nitro claim 1 , and methoxycarbonyl.13. The method of wherein each Ris independently selected from cyclopropyl claim 12 , tert-butyl claim 12 , bromo claim 12 , 4-tert-butylphenyl claim 12 , and phenyl that is substituted at the 4-position with halo.14. The method of wherein each Ris ...

Подробнее
17-04-2014 дата публикации

LIPID-LOWERING ANTIDIABETIC AGENT

Номер: US20140107360A1
Принадлежит: THETIS PHARMACEUTICALS LLC

A composition which includes a salt of metformin and the use of the composition for treatment of or use in prediabetes, diabetes, lowering triglycerides and/or other conditions in mammals. 144-. (canceled)45. A pharmaceutical composition comprising a salt of metformin and an omega-3 polyunsaturated fatty acid selected from the group consisting of eicosapentaenoic acid and docosahexaenoic acid , and mixtures thereof , the composition having an aqueous solubility of at least 50 mg/ml under standard conditions.46. The pharmaceutical composition of claim 45 , wherein the omega-3 polyunsaturated fatty acid is eicosapentaenoic acid.47. The pharmaceutical composition of claim 45 , wherein the omega-3 polyunsaturated fatty acid is docosahexaenoic acid.48. The pharmaceutical composition of claim 45 , wherein the omega-3 polyunsaturated fatty acid is a mixture of eicosapentaenoic acid and docosahexaenoic acid.49. The pharmaceutical composition of claim 45 , wherein the composition is prepared by a process comprising the following stepsadding dropwise at room temperature to a concentrated solution of metformin free base in acetonitrile either eicosapentaenoic acid, docosahexaenoic acid, or a mixture thereof,stirring the reaction mixture for one hour at room temperature in a container protected from light,chilling the reaction mixture to 0 C. for one hour,filtering the chilled reaction mixture under an atmosphere of nitrogen, anddrying the mixture to a powder. The present application claims priority from U.S. provisional patent application 61/461,113 filed on Jan. 12, 2011, the contents of which are herein incorporated by reference.1. Field of the InventionThe present invention relates to salts of poly unsaturated fatty acids with biguanides.2. Technical BackgroundDiabetes mellitus has become pandemic and according to a forecast by the World Health Organization, there will be a sharp increase in the number of diabetic patients by the year 2030. This is an ominous forecast, ...

Подробнее
16-03-2017 дата публикации

GUANIDINE COMPOUNDS AND USE THEREOF

Номер: US20170073331A1
Принадлежит: IMMUNOMET THERAPEUTICS INC.

The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer, by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism. 120-. (canceled)23. The compound of claim 22 , wherein each of R claim 22 , Rand Ris hydrogen in chemical formula 2.25. The compound of claim 24 , wherein each of R claim 24 , Rand Ris hydrogen in chemical formula 3.27. The compound of claim 25 , wherein each of R claim 25 , Rand Ris hydrogen in chemical formula 4.29. The compound of claim 28 , wherein each of R claim 28 , Rand Ris hydrogen in chemical formula 5.30. The compound of claim 21 , wherein each of Rand Ris hydrogen in chemical formula 6.31. A compound selected from the group consisting of the following compounds claim 21 , and pharmaceutically acceptable salts claim 21 , pharmaceutically acceptable solvates claim 21 , prodrug forms of claim 21 , and derivatives of claim 21 , such compounds:N-1-(3,4-dichloro)phenethylbiguanide,N-1-(2,5-dichloro)phenethylbiguanide,N-1-(2-chloro)phenethylbiguanide,N-1-(2,4-dichloro)phenethylbiguanide,N-1-(3-fluoro)phenethylbiguanide,N-1-(4-trifluoromethoxy)phenethylbiguanide,N-1-(4-trifluoromethyl)phenethylbiguanide,N-1-(3-methoxy)phenethylbiguanide,N-1-(2-fluoro)phenethylbiguanide,N-1-(4-methyl)phenethylbiguanide,N-1-(4-methanesulphoneamine)phenethylbiguanide,N-1-(4-(N,N-dimethyl)phenethylbiguanide,N-1-(4-phenoxy)phenethylbiguanide,N-1-(4-isopropyl)phenethylbiguanide,N-1-(3,4-dimethyl)phenethylbiguanide,N-1-(2,4-dimethyl)phenethylbiguanide,N-1-(4-fluoro-2-methyl)phenethylbiguanide,N-1-(2,4-dimethyl)benzylbiguanide,N-1-(4-fluoro-3-methoxy)phenethylbiguanide,N-1-(3,4-difluoro)phenethylbiguanide,N-1-(2-morpholinoethyl)biguanide,N-1-(2-methyl)phenethylbiguanide,N-1-(3-bromo-4-fluoro)benzylbiguanide,N-1 ...

Подробнее
07-04-2016 дата публикации

N-PHOSPHONOMETHYLGLYCINE GUANIDINE DERIVATIVE SALTS

Номер: US20160095317A1
Принадлежит:

The present invention provides guanidine compounds and salts thereof that may be useful, for example, in the preparation of herbicidal compositions. The compounds may be used, for example, to prepare N-phosphonomethylglycine guanidine salts having improved herbicidal efficacy over glyphosate alone. 2. The compound of wherein R claim 1 , R claim 1 , Rand Rare independently hydrogen or C-Calkyl.3. The compound of wherein Ris 3 claim 1 ,6 claim 1 ,9 claim 1 ,12 claim 1 ,15 claim 1 ,18-hexaazatriacontyl or (2 claim 1 ,3-diamino)tallow and R claim 1 , R claim 1 , Rand Rare hydrogen.4. The compound of wherein Ris 3 claim 1 ,6 claim 1 ,9 claim 1 ,12 claim 1 ,15 claim 1 ,18-hexaazatriacontyl or (2 claim 1 ,3-diamino)tallow and R claim 1 , R claim 1 , Rand Rare methyl.5. The compound of wherein Ris polyethyleneimino and R claim 1 , R claim 1 , Rand Rare hydrogen.6. The compound of wherein Ris polyethyleneimino and R claim 1 , R claim 1 , R claim 1 , and Rare methyl.7. An aqueous herbicidal composition comprising the compound of and an herbicide component comprising one or more herbicides.8. The composition of wherein the herbicide component comprises glyphosate.9. The composition of wherein the herbicide component comprises one or more water-soluble herbicides selected from the group consisting of acifluorfen claim 7 , acrolein claim 7 , amitrole claim 7 , asulam claim 7 , benazolin claim 7 , bentazon claim 7 , bialaphos claim 7 , bromacil claim 7 , bromoxynil claim 7 , chloramben claim 7 , chloroacetic acid claim 7 , clopyralid claim 7 , 2 claim 7 ,4-D claim 7 , 2 claim 7 ,4-DB claim 7 , dalapon claim 7 , dicamba claim 7 , dichlorprop claim 7 , difenzoquat claim 7 , diquat claim 7 , endothall claim 7 , fenac claim 7 , fenoxaprop claim 7 , flamprop claim 7 , flumiclorac claim 7 , fluoroglycofen claim 7 , flupropanate claim 7 , fomesafen claim 7 , fosamine claim 7 , glufosinate claim 7 , imazameth claim 7 , imazamethabenz claim 7 , imazamox claim 7 , imazapic claim 7 , ...

Подробнее
19-04-2018 дата публикации

Tricyclic Amino Containing Compounds for Treatment or Prevention of Symptoms Associated with Endocrine Dysfunction

Номер: US20180104243A1
Принадлежит:

The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes. 2. The method of claim 1 , wherein the subject is menopausal or perimenopausal woman.3. The method of claim 1 , wherein the subject is menstruating or expecting to menstruate with a week.4. The method of claim 1 , wherein the subject is a woman diagnosed with vulvodynia.5. The method of claim 1 , wherein the pharmaceutical composition is administered in combination with another active agent.6. The method of claim 1 , wherein the pharmaceutical composition is administered in combination with an agonist or antagonist of an estrogen receptor.7. The method of claim 1 , wherein the pharmaceutical composition is administered in combination with tamoxifen.8. The method of claim 1 , wherein the pharmaceucial composition is administered in combination with an antiandrogen.9. The method of claim 1 , wherein the subject is a man with prostate cancer.10. The method of Claim claim 1 , wherein the pharmaceutical composition is administered in combination with spironolactone claim 1 , cyproterone claim 1 , flutamide claim 1 , nilutamide claim 1 , bicalutamide claim 1 , finasteride claim 1 , or dutasteride.11. The method of claim 1 , wherein said compound is N-(4-((pyrimidin-2-ylamino)methyl)benzyl)-pyrimidin-2-amine or pharmaceutically acceptable salt thereof12. The method of claim 1 , further comprising the step of administering the pharmaceutical composition to the subject after claim 1 , before claim 1 , or during a surgery selected from a hysterectomy claim 1 , oophorectomy claim 1 , partial oophorectomy claim 1 , unilateral salpingo-oophorectomy claim 1 , bilaterial salpingo-oophorectomy or combination thereof.13. The use of a compound of in the production of a medicament for the treatment or prevention of hot flashes. This application claims priority to U.S. Provisional Application Number 61/ ...

Подробнее
10-05-2018 дата публикации

ANTI-INFLAMMATORY DRUG AND USES THEREOF

Номер: US20180127358A1

An anti-inflammatory drug containing a G0/G1 switch 2 (G0S2) inhibitor as an active ingredient is useful as a novel anti-inflammatory drug. 1. (canceled)2. (canceled)3. (canceled)4. (canceled)5. (canceled)6. (canceled)7. A method for screening an anti-inflammatory drug , comprising:a step of measuring an intracellular expression level of a G0S2 gene in the presence of a test substance; anda step of determining that the test substance is an anti-inflammatory drug, in the case where the expression level is decreased as compared to the intracellular expression level of a G0S2 gene in the absence of the test substance.8. A method for screening an anti-inflammatory drug , comprising:a step of measuring an activity of an Hsd17b4 protein in the presence of a test substance; anda step of determining that the test substance is an anti-inflammatory drug, in the case where the activity is decreased as compared to the activity of an Hsd17b4 protein in the absence of the test substance.11. The method according to claim 10 , wherein the inflammation-related disease is hepatitis or hepatoma. The present invention relates to an anti-inflammatory drug and uses thereof. More specifically, the present invention relates to an anti-inflammatory drug, a method for screening an anti-inflammatory drug, and a novel compound. Priority is claimed on Japanese Patent Application No. 2015-14829 filed on Jan. 28, 2015 and Japanese Patent Application No. 2015-176745 filed on Sep. 8, 2015, the contents of which are incorporated herein by reference.Inflammation is one of the symptoms found in various diseases. Currently, many pharmaceutical products that suppress inflammation are available, but there are still diseases with high unmet medical needs among inflammation-related diseases. The inflammation-related disease may be, for example, cancer. Cancer is one of the refractory diseases accompanied by inflammation. Cancer is the leading cause of death in Japan, and the number of deaths due to cancer ...

Подробнее
10-05-2018 дата публикации

NITRITE SALTS OF 1,1-DIMETHYLBIGUANIDE, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE

Номер: US20180127359A1
Принадлежит:

Provided herein are nitrite salts of 1,1-dimethylbiguanide; and isotopic variants thereof; and pharmaceutically acceptable hydrates and solvates thereof. Also provided herein are their pharmaceutical compositions and methods of use for treating, preventing, or ameliorating one or more symptoms of diseases associated with and/or caused by an abnormal blood glucose level. Further provided herein are methods of their use for treating, preventing, or ameliorating one or more symptoms of a cardiovascular disease. 1. A solid nitrite salt of 1 ,1-dimethylbiguanide , or an isotopic variant thereof or a pharmaceutically acceptable hydrate or solvate thereof.2. An isolated nitrite salt of 1 ,1-dimethylbiguanide , or an isotopic variant thereof or a pharmaceutically acceptable hydrate or solvate thereof.3. The nitrite salt of claim 1 , wherein the nitrite salt is 1 claim 1 ,1-dimethylbiguanide mononitrite claim 1 , or an isotopic variant thereof; or a pharmaceutically acceptable hydrate or solvate thereof.4. The nitrite salt of claim 1 , wherein the nitrite salt is 1 claim 1 ,1-dimethylbiguanide dinitrite claim 1 , or an isotopic variant thereof or a pharmaceutically acceptable hydrate or solvate thereof.5. The nitrite salt of claim 1 , wherein the nitrite salt is in a crystalline form.6. A composition comprising the nitrite salt of claim 1 , or an isotopic variant thereof or a pharmaceutically acceptable hydrate or solvate thereof and a metal nitrite.7. The composition of claim 6 , comprising no less than about 90% of the nitrite salt.810-. (canceled)11. The composition of claim 6 , comprising no greater than about 10% of the metal nitrite.1217-. (canceled)18. A pharmaceutical composition comprising the nitrite salt of claim 1 , or an isotopic variant thereof; or a pharmaceutically acceptable hydrate or solvate thereof; and a pharmaceutically acceptable excipient.19. The pharmaceutical composition of claim 18 , wherein the pharmaceutical composition is formulated for single ...

Подробнее
22-09-2022 дата публикации

Photobase Generator, Compound, Photoreactive Composition, and Reaction Product

Номер: US20220298268A1
Автор: Arimitsu Koji
Принадлежит:

A photobase generator includes a compound including a first skeleton represented by the following formula (a), and a second skeleton including a nitrogen atom bonding to a bonding position of the first skeleton to form an amide group, wherein the compound generates a base, in which a hydrogen atom is bonding with the nitrogen atom of the second skeleton, by light irradiation, and the pKa of a conjugate acid of the base in water is 12 or more. In formula (a), G is a divalent aromatic group, and * represents the bonding position with the nitrogen atom. 5. (canceled)7. A photoreactive composition , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the photobase generator according to ; and'}a base-reactive compound,wherein the base-reactive compound includes a functional group that is converted, by the action of a base, into a group exhibiting reactivity, or includes a group that reacts in response to the action of a base.8. A reaction product obtained by reacting the photoreactive composition according to .9. A photoreactive composition claim 7 , comprising:{'claim-ref': {'@idref': 'CLM-00002', 'claim 2'}, 'the photobase generator according to ; and'}a base-reactive compound,wherein the base-reactive compound includes a functional group that is converted, by the action of a base, into a group exhibiting reactivity, or includes a group that reacts in response to the action of a base.10. A photoreactive composition claim 7 , comprising:{'claim-ref': {'@idref': 'CLM-00003', 'claim 3'}, 'the photobase generator according to ; and'}a base-reactive compound,wherein the base-reactive compound includes a functional group that is converted, by the action of a base, into a group exhibiting reactivity, or includes a group that reacts in response to the action of a base. The present invention relates to a photobase generator, a compound, a photoreactive composition, and a reaction product.Photopolymerizable materials to be polymerized when irradiated with light are ...

Подробнее
14-07-2016 дата публикации

MOISTURE CURABLE COMPOSITIONS

Номер: US20160200875A1
Принадлежит: Momentive Performance Materials Inc.

The present invention provides curable compositions comprising non-tin metal accelerators that accelerate the condensation curing of moisture-curable silicones/non-silicones. In particular, the present invention provides an accelerator comprising guanidine-containing compounds that are particularly suitable as replacements for organotin in sealant and RTV formulations. Further, the compositions employing a guanidine-containing compound is comparable or superior to organotin such as DBTDL, exhibits certain behavior in the presence of components that allow for tuning or adjusting the cure characteristics of the compositions, and provides good adhesion and storage stability. 1. A composition for forming a curable polymer composition comprising:(A) a polymer having at least a reactive silyl group;(B) a crosslinker or chain extender; and(C) a condensation accelerator comprising a guanidine-containing compound, wherein the guanidine-containing compound comprises a plurality of guanidine functional groups.2. The composition of claim 1 , wherein the guanidine-containing compound comprises two guanidine functional groups.3. The composition of claim 1 , wherein the guanidine-containing compound comprises three guanidine functional groups.4. The composition of claim 1 , wherein the guanidine-containing compound comprises four guanidine functional groups.6. The composition of claim 5 , wherein R-Rare individually chosen from branched or straight chain C-Calkyl radical claim 5 , and Ris chosen from a C-Calkylene.8. The composition of claim 5 , wherein R-Rare independently chosen from a branched or straight chain C-Calkyl radical claim 5 , and Ris chosen from an alkylene comprising a carbocycle.9. The composition of claim 8 , wherein the carbocycle comprises a bridging group claim 8 , a fused ring claim 8 , or a fused ring system with at least one ring in the fused ring system comprising a bridging group.14. The composition of comprising from about 0.0001 to about 10 parts per ...

Подробнее
05-08-2021 дата публикации

Surfactant composition and method for treating bitumen froth

Номер: US20210238482A1
Принадлежит: KEMIRA OYJ

The invention relates to a surfactant composition comprising an ionic liquid prepared from an unsubstituted or substituted primary, secondary or tertiary amine, or from an unsubstituted or substituted pyridine, amidine or guanidine with at least one fatty acid and/or resin acid. The invention also relates to a method for treating bitumen froth from a separation process, where bitumen is separated from mineral solids. The method comprises addition of said surfactant composition to the diluent and/or to the froth before phase separation.

Подробнее
19-08-2021 дата публикации

COMPOUNDS AND USES FOR THE TREATMENT AND PREVENTION OF DISEASES AND CONDITIONS ASSOCIATE WITH OR AGGREVATED BY IMPARED MITOPHAGY

Номер: US20210253511A1

The present invention provides compounds and methods for the treatment and prevention of diseases and conditions associate with or aggravated by impaired mitophagy. 2. A method according to claim 1 , wherein L is straight or branched C-Calkylene.3. A method according to claim 1 , wherein L is interrupted by at least one of C-Ccycloalkylene claim 1 , C-Ccycloalkenylene claim 1 , C-Ccycloalkynylene claim 1 , aryl claim 1 , heteroaryl claim 1 , heteroatom and any combinations thereof.412.-. (canceled)13. A method according to claim 1 , wherein Rand Rare each —C(═NR)NRR.14. A method according to claim 1 , wherein Rand Rare each selected from —NRRand —NRRR.15. A method according to claim 1 , wherein Rand Rare each selected from —NRC(═N)NRRand —NRC(═N)—NR—C(═N)—NRR.16. A method according to claim 1 , wherein Rand Rare each —NRNRR.17. A method according to claim 1 , wherein Rand Rare each ═N—R.18. A method according to claim 1 , wherein Rand Rare each —ONRR.22. (canceled)23. (canceled)24. A method according to claim 1 , wherein said impaired mitophagy is in non-regenerative tissue.25. (canceled)26. A method according to claim 1 , wherein said disease claim 1 , disorder claim 1 , symptom claim 1 , which is caused by claim 1 , associated with claim 1 , or aggravated by impaired mitophagy is a neurodegenerative disease claim 1 , disorder and condition associated therewith.27. A method according to claim 1 , wherein said disease claim 1 , disorder claim 1 , symptom claim 1 , which is caused by claim 1 , associated with claim 1 , or aggravated by impaired mitophagy is an age-related disease claim 1 , disorder and condition associated therewith.28. A method according to claim 1 , wherein said disease claim 1 , disorder claim 1 , symptom claim 1 , which is caused by claim 1 , associated with claim 1 , or aggravated by impaired mitophagy is selected from Parkinson's disease claim 1 , Alzheimer's disease claim 1 , dementia claim 1 , congestive heart failure claim 1 , sarcopenia ...

Подробнее
30-10-2014 дата публикации

COMPOSITIONS AND METHODS RELATING TO PROLIFERATIVE DISEASES

Номер: US20140322304A1
Принадлежит:

Anti-cancer compositions and methods are described herein. In particular, compositions including one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described. Methods for treatment of pathological conditions particularly cancer, in a subject using one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described herein. 1. An anti-cancer pharmaceutical composition , comprising:leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and/or an abietic acid derivative and a pharmaceutically acceptable carrier.2. The pharmaceutical composition of claim 1 , wherein the compound is selected from the group consisting of: abietyl alcohol/GPR-8 [(1R claim 1 ,4aR)-1 claim 1 ,4a-dimethyl-7-(propan-2-yl)-1 claim 1 ,2 claim 1 ,3 claim 1 ,4 claim 1 ,4a claim 1 ,4b claim 1 ,5 claim 1 ,6 claim 1 ,10 claim 1 ,10a-decahydrophenanthren-1-yl]methanol; abietylamine/GPR-3 {[(1R claim 1 ,4aR)-1 claim 1 ,4a-dimethyl-7-(propan-2-yl)-1 claim 1 ,2 claim 1 ,3 claim 1 ,4 claim 1 ,4a claim 1 ,4b claim 1 ,5 claim 1 ,6 claim 1 ,10 claim 1 ,10a-decahydrophenanthren-1-yl]methyl}amine; abieticamide/GPR-2 (1R claim 1 ,4aR)-1 claim 1 ,4a-dimethyl-7-(propan-2-yl)-1 claim 1 ,2 claim 1 ,3 claim 1 ,4 claim 1 ,4a claim 1 ,4b claim 1 ,5 claim 1 ,6 claim 1 ,10 claim 1 ,10a-decahydrophenanthrene-1-carboxamide; N-methylabieticamide/GPR-6 (1R claim 1 ,4aR)-N claim 1 ,1 claim 1 ,4a-trimethyl-7-(propan-2-yl)-1 claim 1 ,2 claim 1 ,3 claim 1 ,4 claim 1 ,4a claim 1 ,4b claim 1 ,5 claim 1 ,6 claim 1 ,10 claim 1 ,10a-decahydrophenanthrene-1-carboxamide; N-methylabietylamine/GPR-7 {[(1R claim 1 ,4aR)-1 claim 1 ,4a-dimethyl-7-(propan-2-yl)-1 claim 1 ,2 claim 1 ,3 claim 1 ,4 claim 1 ,4a claim 1 ,4b claim 1 ,5 claim 1 ,6 claim 1 ,10 claim 1 ,10a-decahydrophenanthren-1-yl]methyl}(methyl)amine; N claim 1 ,N-diethylabieticamide/GPR-11 (1R claim 1 ,4aR)-N claim ...

Подробнее
13-09-2018 дата публикации

BIGUANIDE DERIVATIVE, A PREPARATION METHOD THEREOF, AND A PHARMACEUTICAL COMPOSITION CONTAINING THE BIGUANIDE DERIVATIVE AS AN ACTIVE INGREDIENT

Номер: US20180256520A1
Принадлежит:

A biguanide derivative compound with N1-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPKα and inhibition of cancer cell proliferation in a low dose, compared to conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc. 2. The method of claim 1 , wherein R claim 1 , R claim 1 , Rand Rare independently hydrogen or a non-hydrogen substituent selected from the group consisting of unsubstituted Calkyl; Calkyl substituted with at least one non-hydrogen substituent selected from the group consisting of unsubstituted Ccycloalkyl claim 1 , Caryl claim 1 , Cheteroaryl claim 1 , hydroxyl claim 1 , halogen and Calkoxycarbonyl; unsubstituted Ccycloalkyl; Calkoxy; Caryl; Cheteroaryl; hydroxyl; and halogen claim 1 , and{'sub': 1-4', '1-4, 'the aryl and heteroaryl are unsubstituted or substituted with at least one non-hydrogen substituent selected from the group consisting of Calkyl, Calkoxy, hydroxyl and halogen.'}3. The method of claim 2 , wherein Rand Rare independently non-hydrogen substituents selected from the group consisting of unsubstituted Calkyl; Calkyl substituted with at least one non-hydrogen substituent selected from the group consisting of unsubstituted Ccycloalkyl claim 2 , Caryl claim 2 , Cheteroaryl and Calkoxycarbonyl; unsubstituted Ccycloalkyl; Caryl; and Cheteroaryl claim 2 ,{'sub': 2', '3', '1-7', '5-12', '5-12', '1-6', '5-12, 'Rand Rare hydrogen; unsubstituted Calkyl; Caryl; Cheteroaryl or Calkyl substituted with Cheteroaryl, and'}{'sub': 1-4', '1-4, 'the aryl and heteroaryl are unsubstituted or substituted with at least one non-hydrogen ...

Подробнее
21-09-2017 дата публикации

COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS

Номер: US20170266326A1
Принадлежит: Lantheus Medical Imaging, Inc.

The present invention relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. In some embodiments, methods and compositions for assessing perfusion and innervation mismatch in a portion of a subject are provided.

Подробнее
06-10-2016 дата публикации

Compounds and methods for treating candidiasis and aspergillus infections

Номер: US20160287586A1

The present disclosure provides compounds, or pharmaceutically acceptable salts thereof, for killing or inhibiting the growth of a Candida or Aspergillus species or preventing or treating a mammal having candidiasis (oral and/or disseminated) or an Aspergillus infection.

Подробнее
13-10-2016 дата публикации

PHOTOBASE GENERATOR

Номер: US20160299429A1
Принадлежит: SAN APRO LTD.

Provided are a photobase generator having higher sensitivity to light than do conventional photobase generators, and a photosensitive resin composition containing the photobase generator. The present invention is a photobase generator characterized in containing a salt represented by general formula (1). (In formula (1), R-Rare mutually independent groups represented by general formula (2), C1-18 alkyl groups, or Ar, with at least one being a group represented by general formula (2); in formula (2), (D) is a divalent group bonded on at least one side to elemental boron, and Aris the same as the aforementioned Ar; and Q is a monovalent onium cation.) 3. The photobase generator according to claim 1 , wherein an absorption wavelength which Ar as one of Rto Rin general formula (1) has and an absorption wavelength which Arin general formula (2) has satisfy an inequality of Ar Подробнее

26-10-2017 дата публикации

Linear guanidine derivatives, methods of preparation and uses thereof

Номер: US20170304235A1
Принадлежит: Lead Discovery Siena Srl

The present invention relates to linear guanidine derivatives, methods of preparation, uses and pharmaceutical compositions thereof. The compounds of Formulas 1 or 2 exhibit high antimicrobial activity against Gram positive and Gram negative bacteria.

Подробнее
31-12-2015 дата публикации

BIGUANIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS AN ACTIVE INGREDIENT

Номер: US20150376123A1
Принадлежит:

A biguanide derivative compound with N4-N5 substitution, which is represented by Formula 1, or a pharmaceutically acceptable salt thereof, a method of preparing the same, and a pharmaceutical composition containing the same as an active ingredient are provided. The biguanide derivative may exhibit excellent effect on activation of AMPK and inhibition of cancer cell proliferation in a low dose, compared with conventional drugs, and thus, may be useful to treat diabetes mellitus, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovarian syndrome, metabolic syndrome, cancer, etc. 2. The method of claim 1 , wherein the diabetes mellitus is insulin-independent mellitus.3. The method of claim 1 , wherein the cancer is breast cancer claim 1 , colorectal cancer claim 1 , gastric cancer claim 1 , liver cancer claim 1 , lung cancer claim 1 , blood cancer claim 1 , prostate cancer claim 1 , brain cancer claim 1 , pancreatic cancer claim 1 , ovarian cancer claim 1 , or endometrial cancer.4. The method of claim 1 , wherein the compound of Formula 1 is N4-cyclopentyl-N5-benzyl biguanide; N4-cycloheptyl-N5-benzyl biguanide; N4-(furan-2-yl)methyl-N5-benzyl biguanide; N4-1-adamantyl-N5-(phenethyl)biguanide; N4-phenyl-N5-(phenethyl)biguanide; N4-(4-chloro)phenyl-N5-(phenethyl)biguanide; N4-(4-trifluoromethyl)phenyl-N5-(phenethyl)biguanide; N4-(furan-2-yl)methyl-N5-(phenethyl)biguanide; N4-benzyl-N5-(phenethyl)biguanide; N4-(4-fluoro)benzyl-N5-(phenethyl)biguanide; N4 claim 1 ,N5-di(phenethyl)biguanide; N4-methyl-N5 claim 1 ,N5-(benzyl)(methyl)biguanide; N4-(4-methoxyl)benzyl-N5 claim 1 ,N5-(1-naphthylmethyl)(methyl) biguanide; or N4-(phenethyl)-N5 claim 1 ,N5-(phenethyl)(methyl)biguanide.5. The method of claim 1 , wherein the pharmaceutically acceptable salt is a salt with an acid selected from the group consisting of formic acid claim 1 , acetic acid claim 1 , propionic acid claim 1 , lactic acid claim 1 , butyric acid ...

Подробнее
28-11-2019 дата публикации

ANTI-INFLAMMATORY DRUG AND USES THEREOF

Номер: US20190359560A1

An anti-inflammatory drug containing a G0/G1 switch 2 (G0S2) inhibitor as an active ingredient is useful as a novel anti-inflammatory drug. 19.-. (canceled)11. The method according to claim 10 , wherein the inflammation-related disease is hepatitis or hepatoma. The present invention relates to an anti-inflammatory drug and uses thereof. More specifically, the present invention relates to an anti-inflammatory drug, a method for screening an anti-inflammatory drug, and a novel compound. This application is a divisional application of U.S. patent application Ser. No. 15/545,831, filed Dec. 12, 2017, which is a National Stage Application of International Patent Application No. PCT/JP2016/052470, filed Jan. 28, 2016, which claims the benefit of Japanese Patent Application No. 2015-14829 filed on Jan. 28, 2015 and Japanese Patent Application No. 2015-176745 filed on Sep. 8, 2015, the contents of which are incorporated herein by reference.Inflammation is one of the symptoms found in various diseases. Currently, many pharmaceutical products that suppress inflammation are available, but there are still diseases with high unmet medical needs among inflammation-related diseases. The inflammation-related disease may be, for example, cancer. Cancer is one of the refractory diseases accompanied by inflammation. Cancer is the leading cause of death in Japan, and the number of deaths due to cancer has been increasing year by year all over the world, which is thus regarded as a problem.Cancer is found in many organs, but especially hepatoma (hepatocellular cancer) is a cancer type with high mortality rate and recurrence rate. About 90% of the causes of hepatoma are due to viral infection, and hepatoma develops through pathological conditions such as hepatitis starting after viral infection or long-term chronic hepatitis of hepatic cirrhosis (see, for example, NPL 1). Among the pathological conditions, chronic inflammation is known to accelerate the expression of cancer cells ...

Подробнее
24-12-2020 дата публикации

Compositions, methods, and systems for the synthesis and use of imaging agents

Номер: US20200397927A1
Принадлежит: Lantheus Medical Imaging Inc

The present invention relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in 18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. In some embodiments, methods and compositions for assessing perfusion and innervation mismatch in a portion of a subject are provided.

Подробнее
17-09-1996 дата публикации

Salts of pyromellitic acid, a process for their preparation, and their use

Номер: US5556937A
Автор: Elmar Wolf, Rainer Gras
Принадлежит: Huels AG

The invention relates to salts of pyromellitic acid which comprise 1 mol of pyromellitic acid and 0.5. to 2 mol of a guanidine of the following composition: ##STR1## in which R, R 1 , R 2 , R 3 and R 4 are identical or different radicals from the group consisting of hydrogen, alkyl, cycloalkyl and aromatic hydrocarbon residues having 1 to 8 carbon atoms, and R 1 and R 2 and R 3 and R 4 may form a joint ring which may contain an oxygen atom as heteroatom. Also claimed are the preparation of the salts and their use for matt epoxide and hybrid powder coatings.

Подробнее
22-06-2011 дата публикации

具有胍衍生物的胺混合物

Номер: CN102105440A
Принадлежит: BASF SE

本发明涉及一种包含至少三种硬化剂组分a1)、a2)和b)的混合物,其中硬化剂组分a1)与a2)之比为0.1-10∶1,硬化剂组分b)基于混合物以5-55重量%存在,还涉及一种制备所述混合物的方法,本发明混合物在使环氧树脂固化中的用途,具有环氧树脂的本发明混合物作为粘合剂的用途,以及用本发明混合物固化的环氧树脂。

Подробнее
15-03-1986 дата публикации

熱現像感光材料

Номер: JPS6152638A
Принадлежит: Fuji Photo Film Co Ltd

(57)【要約】本公報は電子出願前の出願データであるた め要約のデータは記録されません。

Подробнее
10-10-2012 дата публикации

双胍衍生物、其制备方法以及包含其作为活性成分的药物组合物

Номер: CN102725264A
Принадлежит: Hanall Biopharma Co Ltd

本发明提供了具有N4-N5取代的式1所示的双胍衍生物或其可药用盐、其制备方法和包含所述双胍衍生物作为活性成分的药物组合物。与常规药物相比,甚至低剂量的本发明双胍衍生物也显示出极佳的AMPKα活化作用和癌细胞增殖抑制作用,这使其可用于治疗糖尿病、肥胖症、高血脂、高胆固醇血症、脂肪肝、冠状动脉病、骨质疏松、多囊卵巢综合征、代谢综合征、癌症等。

Подробнее
28-12-2021 дата публикации

Borate-based base generator, and base-reactive composition comprising such base generator

Номер: KR102343473B1

에폭시계 화합물 등의 염기 반응성 화합물과 혼합한 상태로 장기간 보존한 경우에도 당해 염기 반응성 화합물과 반응하는 일이 없어 보존안정성이 높은 조성물로 할 수 있으며, 또한 광(활성 에너지선)의 조사나 가열에 의해 강염기(구아니딘류, 비구아니드류, 포스파젠류 또는 포스포늄류)를 발생할 수 있는 화합물, 이들을 포함하여 이루어지는 염기 발생제 및 당해 염기 발생제와 염기 반응성 화합물을 함유하는 염기 반응성 조성물을 제공하는 것을 과제로 한다. 본 발명은 일반식 (A)로 표시되는 화합물, 당해 화합물을 포함하여 이루어진 염기 발생제, 당해 염기 발생제 및 염기 반응성 화합물을 함유하는 것을 특징으로 하는 염기 반응성 조성물 등에 관한 것이다. (식 중, R 1 은 알킬기; 할로겐 원자, 알킬기, 알콕시기, 또는 알킬티오기로 치환되어 있어도 좋은 아릴알키닐기; 알케닐기; 2-퓨릴에티닐기; 2-티오페닐에티닐기; 또는 2,6-디티아닐기를 나타내고, R 2 ~R 4 는 각각 독립적으로 알킬기; 할로겐 원자, 알킬기, 알콕시기, 또는 알킬티오기로 치환되어 있어도 좋은 아릴알키닐기; 할로겐 원자, 알킬기, 알콕시기, 또는 알킬티오기로 치환되어 있어도 좋은 아릴기; 퓨라닐기; 티에닐기; 또는 N-알킬 치환 피롤릴기를 나타내고, Z + 는 구아니디늄기, 비구아니듐기 또는 포스파제늄기를 갖는 암모늄 양이온, 혹은 포스포늄 양이온을 나타낸다.) Even when stored for a long period of time in a state of mixing with a base-reactive compound such as an epoxy-based compound, it does not react with the base-reactive compound, resulting in a composition with high storage stability. To provide a compound capable of generating a strong base (guanidine, biguanide, phosphazene or phosphonium) by make it a task The present invention relates to a compound represented by the general formula (A), a base generator comprising the compound, a base-reactive composition comprising the base generator and a base-reactive compound, and the like. (wherein, R 1 is an alkyl group; an arylalkynyl group optionally substituted with a halogen atom, an alkyl group, an alkoxy group, or an alkylthio group; an alkenyl group; a 2-furylethynyl group; a 2-thiophenylethynyl group; or 2, represents a 6-dithianyl group, and R 2 to R 4 are each independently an alkyl group; an arylalkynyl group optionally substituted with a halogen atom, an alkyl group, an alkoxy group, or an alkylthio group; a halogen atom, an alkyl group, an alkoxy group, or an alkylthio group optionally substituted aryl; furanoid group; a thienyl group; or a substituted alkyl N- pyrrolyl, Z + represents an ammonium cation, or a phosphonium cation having guanidinyl nyumgi, acetabular no dyumgi ...

Подробнее
25-03-2015 дата публикации

可固化聚硅氧烷组合物

Номер: CN104470983A
Принадлежит: 3M Innovative Properties Co

本发明公开了一种可固化组合物,该可固化组合物包含(a)包含具有至少两个羟基甲硅烷基部分的反应性硅烷官能团的至少一种聚有机硅氧烷、氟化的聚有机硅氧烷或它们的组合;(b)包含具有至少两个氢甲硅烷基部分的反应性硅烷官能团的至少一种聚有机硅氧烷、氟化的聚有机硅氧烷或它们的组合;和(c)催化剂组合物,所述催化剂组合物包含(1)至少一种选自脒、胍、磷腈、有机非离子超强碱以及它们的组合的碱,和(2)至少一种路易斯酸;其中所述组分(a)和(b)中的至少一者具有至少3的平均反应性硅烷官能团。

Подробнее
08-03-1984 дата публикации

スパガリン関連化合物およびその製造法

Номер: JPS5942356A
Принадлежит: Microbial Chemistry Research Foundation

(57)【要約】本公報は電子出願前の出願データであるた め要約のデータは記録されません。

Подробнее
14-06-2021 дата публикации

Novel lipids and compositions for the delivery of therapeutics

Номер: KR102264822B1

본 발명은 생체내에서 세포로 치료제 운반을 위한 지질 입자에 유익하게 이용되는 지질을 제공한다. 특히, 본 발명은 다음의 구조 (I)을 가지는 지질을 제시하며, 여기서 구조식 (I)에서 R 1 및 R 2 는 서로 독립적으로 임의로 치환된 C 10 -C 30 알킬, 임의로 치환된 C 10 -C 30 알케닐, 임의로 치환된 C 10 -C 30 알키닐, 임의로 치환된 C 10 -C 30 아실, 또는 -링커-리간드이고; R 3 은 H, 임의로 치환된 C 1 -C 10 알킬, 임의로 치환된 C 2 -C 10 알케닐, 임의로 치환된 C 2 -C 10 알키닐, 알킬헤테로사이클, 알킬포스페이트, 알킬포스포로티오에이트, 알킬포스포로디티오에이트, 알킬포스포네이트, 알킬아민, 하이드록시알킬, ω-아미노알킬, ω-(치환된)아미노알킬, ω-포스포알킬, ω-티오포스포알킬, 임의로 치환된 폴리에틸렌 글리콜 (PEG, mw 100-40K), 임의로 치환된 mPEG (mw 120-40K), 헤테로아릴, 헤테로사이클, 또는 링커-리간드이며; E는 O, S, N(Q), C(O), N(Q)C(O), C(O)N(Q), (Q)N(CO)O, O(CO)N(Q), S(O), NS(O) 2 N(Q), S(O) 2 , N(Q)S(O) 2 , SS, O=N, 아릴, 헤테로아릴, 사이클릭 또는 헤테로사이클이고; Q는 H, 알킬, ω-아미노알킬, ω-(치환된)아미노알킬, ω-포스포알킬 또는 ω-티오포스포알킬이다. The present invention provides lipids that are advantageously used in lipid particles for delivery of therapeutic agents to cells in vivo. In particular, the present invention provides a lipid having the structure (I) wherein R 1 and R 2 are independently of each other optionally substituted C 10 -C 30 alkyl, optionally substituted C 10 -C 30 alkenyl, optionally substituted C 10 -C 30 alkynyl, optionally substituted C 10 -C 30 acyl , or - a linker-ligand; R 3 is H, optionally substituted C 1 -C 10 alkyl, optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, alkylheterocycle, alkylphosphate, alkylphosphorothioate, Alkylphosphorodithioate, alkylphosphonate, alkylamine, hydroxyalkyl, ω-aminoalkyl, ω-(substituted)aminoalkyl, ω-phosphoalkyl, ω-thiophosphoalkyl, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; E is O, S, N(Q), C(O), N(Q)C(O), C(O)N(Q), (Q)N(CO)O, O(CO)N(Q) ), S(O), NS(O) 2 N(Q), S(O) 2 , N(Q)S(O) 2 , SS, O=N, aryl, heteroaryl, cyclic or heterocycle; ; Q is H, alkyl, ω-aminoalkyl, ω-(substituted)aminoalkyl, ω-phosphoalkyl or ω-thiophosphoalkyl.

Подробнее
31-12-2019 дата публикации

Guanidine compounds and use thereof

Номер: KR102061390B1

본 발명은 미토콘드리아의 산화적 인산화 (OXPHOS)를 억제하기 위한 구아니딘 화합물 및 그의 용도에 관한 것이다. 보다 구체적으로, 본 발명은 미토콘드리아의 산화적 인산화를 억제하고 세포 대사를 재프로그래밍함으로써 OXPHOS와 관련된 질환, 특히 암을 예방 또는 치료하기 위한 약학 조성물에 관한 것이다. The present invention relates to guanidine compounds and their use for inhibiting oxidative phosphorylation (OXPHOS) of mitochondria. More specifically, the present invention relates to pharmaceutical compositions for preventing or treating diseases associated with OXPHOS, in particular cancer, by inhibiting oxidative phosphorylation of mitochondria and reprogramming cell metabolism.

Подробнее
15-02-2017 дата публикации

Borate-based base generator, and base-reactive composition comprising such base generator

Номер: CN106414461A
Автор: 筑场康佑, 酒井信彦
Принадлежит: Wako Pure Chemical Industries Ltd

本发明的课题在于提供一种化合物、包含这些化合物而成的产碱剂以及含有该产碱剂与碱反应性化合物的碱反应性组合物,该化合物即使在与环氧系化合物等碱反应性化合物混合的状态下长期间保存时,也不与该碱反应性化合物反应,能够制成保存稳定性高的组合物,且能够通过光(活性能量射线)的照射、加热产生强碱(胍类、双胍类、磷腈类或鏻类)。本发明涉及通式(A)所表示的化合物、包含该化合物而成的产碱剂、以及特征在于含有该产碱剂和碱反应性化合物的碱反应性组合物等。(式中,R 1 表示烷基;可以经卤原子、烷基、烷氧基或烷硫基取代的芳炔基;烯基;2‑呋喃基乙炔基;2‑硫苯乙炔基;或2,6‑二噻烷基,R 2 ~R 4 各自独立地表示烷基;可以经卤原子、烷基、烷氧基或烷硫基取代的芳炔基;可以经卤原子、烷基、烷氧基或烷硫基取代的芳基;呋喃基;噻吩基;或N‑烷基取代吡咯基,Z + 表示具有胍鎓基、双胍鎓基或磷腈鎓基的铵阳离子或鏻阳离子。)

Подробнее
21-10-2015 дата публикации

Mixtures of amines having guanidine derivatives

Номер: KR101562421B1
Принадлежит: 바스프 에스이

본 발명은 적어도 3개의 경화제 성분 a1), a2) 및 b)를 함유하고, 경화제 성분 a1) 대 a2)의 비가 0.1 내지 10 대 1의 범위이고, 경화제 성분 b)가 혼합물에 대해 5 내지 55 중량%로 존재하는 혼합물, 상기 혼합물의 제조 방법, 에폭시 수지를 경화시키기 위한 본 발명에 따른 혼합물의 용도, 접착제로서 에폭시 수지를 가진 본 발명에 따른 혼합물의 용도, 및 본 발명에 따른 혼합물로 경화된 에폭시 수지에 관한 것이다. The present invention relates to a composition comprising at least three hardener components a1), a2) and b), wherein the ratio of hardener component a1) to a2) is in the range of from 0.1 to 10: 1 and the hardener component b) %, The process for preparing the mixture, the use of the mixture according to the invention for curing the epoxy resin, the use of the mixture according to the invention with an epoxy resin as an adhesive, and the epoxy- Resin.

Подробнее
28-05-2002 дата публикации

Compositions for the delivery of negatively charged molecules

Номер: US6395713B1
Принадлежит: Ribozyme Pharmaceuticals Inc

This invention features permeability enhancer molecules, and methods, to increase membrane permeability of negatively charged polymers thereby facilitating cellular uptake of such polymers.

Подробнее
25-09-2019 дата публикации

Silanes containing amidine groups or guanidine groups

Номер: JP6580590B2
Принадлежит: SIKA TECHNOLOGY AG

Подробнее
08-02-2019 дата публикации

Composition for skin permeation comprising cationic molecular transporters and protein

Номер: KR101945498B1
Автор: 이우설, 임정균, 정성기
Принадлежит: 포항공과대학교 산학협력단

본 발명은 양이온성 화합물 및 단백질이 이온 결합된 이온 결합체를 포함하며, 피부 내로 상기 단백질을 전달하기 위한 피부 투과용 조성물에 관한 것으로, 본 발명에 따르면 상기 이온 결합체는 단백질이 세포막 및 피부막을 용이하게 통과할 수 있게 하여, 이를 피부의 표피층 내지 진피층으로 전달할 수 있다. The present invention relates to a skin permeable composition for transferring a protein into skin, which comprises an ionic bond in which a cationic compound and a protein are ionically bonded. According to the present invention, So that it can be transferred to the epidermal layer or the dermal layer of the skin.

Подробнее
01-03-1983 дата публикации

Novel guanidine with large steric space and manufacture

Номер: JPS5835164A

(57)【要約】本公報は電子出願前の出願データであるた め要約のデータは記録されません。

Подробнее
09-02-2017 дата публикации

Biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same

Номер: KR101704683B1

본 발명은 N1-N5-치환된 하기 화학식 1로 표시되는 바이구아나이드 유도체 또는 그의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 유효성분으로 약학 조성물을 제공한다. 본 발명의 바이구아나이드 유도체는 기존 약물에 비해 적은 양으로도 우수한 AMPKα 활성화 효과 및 암세포 증식 억제 효과를 나타내어 당뇨, 비만, 고지혈증, 고콜레스테롤혈증, 지방간, 관상동맥질환, 골다공증, 다낭성 난소증후군, 대사성 증후군, 암 등의 치료를 위해 유용하게 이용될 수 있다. [화학식 1] The present invention provides a N1-N5-substituted biaguanide derivative represented by the following formula (1), a pharmaceutically acceptable salt thereof, a process for producing the same, and a pharmaceutical composition containing the same as an active ingredient. The biguanide derivatives of the present invention exhibit the AMPKa activation effect and the cancer cell proliferation inhibitory effect which are superior to the conventional drugs in a smaller amount than those of the conventional drugs and are useful for the prevention of diabetes, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome, Syndrome, cancer, and the like. [Chemical Formula 1]

Подробнее
08-06-2016 дата публикации

Moisture curable compositions

Номер: CN105658695A
Принадлежит: General Electric Co

本发明提供了包含非锡金属加速剂的可固化组合物,所述非锡金属加速剂加速可湿固化的有机硅/非有机硅的缩合固化。特别地,本发明提供了包含特别适合作为在密封剂和RTV制剂中有机锡替代物的含胍化合物的加速剂。另外,采用含胍化合物的组合物相当或优于有机锡如DBTDL,在允许调整或调节组合物的固化特性的组分存在下显示某些行为,并提供了良好的粘附和存储稳定性。

Подробнее
16-08-2018 дата публикации

Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use

Номер: TW201828932A
Принадлежит: 美商諾沃麥迪斯有限責任公司

本文中提供1,1-二甲基雙胍之亞硝酸鹽;及其同位素變體;及其醫藥上可接受之水合物及溶劑合物。本文中亦提供其醫藥組合物及用於治療、預防或改善與異常血糖含量相關及/或由異常血糖含量所引起之疾病之一或多種症狀之方法。本文中進一步提供其用於治療、預防或改善心血管疾病之一或多種症狀之方法。

Подробнее
23-12-2004 дата публикации

Ionic liquids with guanidinium cations

Номер: DE10325051A1
Принадлежит: Merck Patent GmBH

Die vorliegende Erfindung betrifft Salze mit Guanidinium-Kationen, Verfahren zu ihrer Herstellung sowie ihre Verwendung als ionische Flüssigkeiten. The present invention relates to salts with guanidinium cations, processes for their preparation and their use as ionic liquids.

Подробнее
09-12-2004 дата публикации

Ionic liquids containing guanidinium cations

Номер: WO2004106288A2
Принадлежит: Merck Patent GmBH

The invention relates to salts containing guanidinium cations, to a method for their production and to their use as ionic liquids.

Подробнее
25-08-2020 дата публикации

Phosphorus-containing ionic liquid and preparation method and application thereof

Номер: CN111574560A

本发明公开了一种含磷离子液体及其制备方法和应用。所述含磷离子液体作为添加剂与基础油混合均匀,获得含磷型润滑油。本发明的含磷离子液体作为润滑油添加剂具有优异抗磨减摩性能。

Подробнее
31-10-1990 дата публикации

Process for the preparation of spero guanyl compound

Номер: KR900008137B1

Cpds. of formula (I) and their salts are prepd. In (I) R1 is H, OH or C1-10 aliphatic acyloxy, R2 is residue of alpha or omega amino acid where H atom is removed off from carboxyl gp. except residue of alpha-hydroxyglycin adjacent carbonyl and amino gp. any bond to form acidamide bond, m is 4-6. (I) where R1 is OH, R2 is -NH-CH(OH)-CO, grampositive bacteria and gramnegative bacteria and have remedial and life-spanning effect to mouse leukaemia L-1210, mouse leudamia FL-4, Ehrlich cancer and sarcoma 180(S-180) Spergualin stable in aqueous soln. and having good activity may be otbd.

Подробнее
02-06-1999 дата публикации

Improvements in and relating to guanidine derivatives

Номер: CN1043527C
Принадлежит: Eli Lilly and Co

本发明提供化合物(-)-N″氰基-N-3-吡啶基-N′-1,2,2-三甲基丙基胍的制备方法。

Подробнее
27-08-2006 дата публикации

Bicyclic derivatives of guanidine and their therapeutic using

Номер: RU2282622C2
Принадлежит: Мерк Патент Гмбх

FIELD: organic chemistry, medicine, pharmacy. SUBSTANCE: invention relates to compounds of the general formula (I): wherein A means benzene ring optionally substituted with one or more the following groups: -OR2 wherein R2 mean linear or branched (C 1 -C 5 )-alkyl; X means -CH=, -CH 2 -, -N= or -NH-radical; Y means radical -CH 2 , oxygen or sulfur atom or group -NR7 wherein R7 means hydrogen atom or linear or branched (C 1 -C 5 )-alkyl; R1 means hydrogen atom, linear or branched (C 1 -C 5 )-alkyl, and to pharmaceutically acceptable salts also. Also, invention relates to a pharmaceutical composition showing anti-diabetic activity. The pharmaceutical composition comprises compound of the general formula (I) as an active component and an inert excipient. Invention provides bicyclic derivatives of guanidine eliciting anti-diabetic activity. EFFECT: valuable medicinal properties of compounds and composition. 8 cl, 2 tbl, 4 ex ÐÎÑÑÈÉÑÊÀß ÔÅÄÅÐÀÖÈß RU (19) (11) 2 282 622 (13) C2 (51) ÌÏÊ C07D 277/64 (2006.01) C07D 235/14 (2006.01) C07D 333/58 (2006.01) C07D 209/14 (2006.01) C07D 307/81 (2006.01) ÔÅÄÅÐÀËÜÍÀß ÑËÓÆÁÀ C07C 279/08 (2006.01) ÏÎ ÈÍÒÅËËÅÊÒÓÀËÜÍÎÉ ÑÎÁÑÒÂÅÍÍÎÑÒÈ,A61K 31/343 (2006.01) ÏÀÒÅÍÒÀÌ È ÒÎÂÀÐÍÛÌ ÇÍÀÊÀÌ A61K 31/381 (2006.01) A61K 31/404 (2006.01) A61K 31/4184 (2006.01) (12) A61K 31/155 (2006.01) A61K 31/428 (2006.01) ÎÏÈÑÀÍÈÅ ÈÇÎÁÐÅÒÅÍÈß Ê ÏÀÒÅÍÒÓ (21), (22) Çà âêà: 2003130062/04, 27.02.2002 (24) Äàòà íà÷àëà îòñ÷åòà ñðîêà äåéñòâè ïàòåíòà: 27.02.2002 (73) Ïàòåíòîîáëàäàòåëü(è): ÌÅÐÊ ÏÀÒÅÍÒ ÃÌÁÕ (DE) (30) Êîíâåíöèîííûé ïðèîðèòåò: 21.03.2001 FR 0103843 2 2 8 2 6 2 2 (43) Äàòà ïóáëèêàöèè çà âêè: 10.04.2005 2 2 8 2 6 2 2 R U (56) Ñïèñîê äîêóìåíòîâ, öèòèðîâàííûõ â îò÷åòå î ïîèñêå: N.B. CHAPMAN et al: "Pharmacologically active benzo[b]thiophen derivatives. Analogoues of tryptamine and heteroauxin", JOURNAL OF THE CHEMICAL SOCIETY, SECTION C: ORGANIC CHEMISTRY. 1969, no.12, p.1612-1616. FR 1502346 A, 02.02.1968. US 3428653 A, 18.02.1969. US 4260628 A, 07.04.1981. US ...

Подробнее
10-04-2005 дата публикации

BICYCLIC DERIVATIVES OF GUANIDINE AND THEIR THERAPEUTIC USE

Номер: RU2003130062A

ÐÎÑÑÈÉÑÊÀß ÔÅÄÅÐÀÖÈß (19) RU (51) ÌÏÊ 7 (11) 2003 130 062 (13) A C 07 D 277/64 ÔÅÄÅÐÀËÜÍÀß ÑËÓÆÁÀ ÏÎ ÈÍÒÅËËÅÊÒÓÀËÜÍÎÉ ÑÎÁÑÒÂÅÍÍÎÑÒÈ, ÏÀÒÅÍÒÀÌ È ÒÎÂÀÐÍÛÌ ÇÍÀÊÀÌ (12) ÇÀßÂÊÀ ÍÀ ÈÇÎÁÐÅÒÅÍÈÅ (21), (22) Çà âêà: 2003130062/04, 27.02.2002 (71) Çà âèòåëü(è): ÌÅÐÊ ÏÀÒÅÍÒ ÃÌÁÕ (DE) (30) Ïðèîðèòåò: 21.03.2001 FR 0103843 (43) Äàòà ïóáëèêàöèè çà âêè: 10.04.2005 Áþë. ¹ 10 (74) Ïàòåíòíûé ïîâåðåííûé: Âåñåëèöêà Èðèíà Àëåêñàíäðîâíà (86) Çà âêà PCT: EP 02/02094 (27.02.2002) Àäðåñ äë ïåðåïèñêè: 101000, Ìîñêâà, Ì.Çëàòîóñòèíñêèé ïåð., ä.10, êâ.15, "ÅÂÐÎÌÀÐÊÏÀÒ", È.À.Âåñåëèöêîé (54) ÁÈÖÈÊËÈ×ÅÑÊÈÅ ÏÐÎÈÇÂÎÄÍÛÅ ÃÓÀÍÈÄÈÍÀ È ÈÕ ÒÅÐÀÏÅÂÒÈ×ÅÑÊÎÅ R U Ôîðìóëà èçîáðåòåíè 1. Ñîåäèíåíè îáùåé ôîðìóëû (I) A 2 0 0 3 1 3 0 0 6 2 A ÈÑÏÎËÜÇÎÂÀÍÈÅ â êîòîðîé: À îáîçíà÷àåò áåíçîëüíîå èëè ïèðèäèíîâîå äðî, íåîá çàòåëüíî çàìåùåííîå îäíîé èëè áîëåå èç ñëåäóþùèõ ãðóïï: - ðàçâåòâëåííîé èëè íåðàçâåòâëåííîé (Ñ1-Ñ20)àëêèëüíîé ãðóïïîé, - OR2, ãäå R2 îáîçíà÷àåò: - âîäîðîä, - ðàçâåòâëåííûé èëè íåðàçâåòâëåííûé (Ñ1-Ñ5)àëêèë, - (Ñ3-Ñ8)öèêëîàëêèë, èëè - áåíçèë, - NR3R4, ãäå R3 è R4 îáîçíà÷àþò, íåçàâèñèìî äðóã îò äðóãà: - âîäîðîä, - ðàçâåòâëåííûé èëè íåðàçâåòâëåííûé (Ñ1-Ñ20)àëêèë, - áåíçèë - àöåòèë, - (Ñ3-Ñ8)öèêëîàëêèë, Ñòðàíèöà: 1 RU 2 0 0 3 1 3 0 0 6 2 (87) Ïóáëèêàöè PCT: WO 02/07696 (03.10.2002) R U (85) Äàòà ïåðåâîäà çà âêè PCT íà íàöèîíàëüíóþ ôàçó: 21.10.2003 (72) Àâòîð(û): Æåðàð ÌÓÀÍÅ (FR), Äàíüåëü ÊÐÀÂÎ (FR) A 2 0 0 3 1 3 0 0 6 2 A R U 2 0 0 3 1 3 0 0 6 2 Ñòðàíèöà: 2 R U - èëè, àëüòåðíàòèâíî, R3 è R4 âìåñòå îáðàçóþò öèêë, ñîäåðæàùèé îò 3-õ äî 8-ìè àòîìîâ, âêëþ÷à àòîì àçîòà, - SR5, ãäå R5 îáîçíà÷àåò: - âîäîðîä, - ðàçâåòâëåííûé èëè íåðàçâåòâëåííûé (Ñ1-Ñ5)àëêèë, - (Ñ3-Ñ8)öèêëîàëêèë, èëè - áåíçèë, - ãàëîãåíîì - öèàíî ãðóïïîé - íèòðî ãðóïïîé - CO2R6, ãäå R6 îáîçíà÷àåò: - âîäîðîä èëè - ðàçâåòâëåííûé èëè íåðàçâåòâëåííûé (Ñ1-Ñ5)àëêèë, èëè - òðèôòîðìåòèëüíîé ãðóïïîé, Õ îáîçíà÷àåò ðàäèêàë -ÑÍ=,-ÑÍ2-, -N= èëè -NH-, Y îáîçíà÷àåò ðàäèêàë CH2, àòîì êèñëîðîäà èëè ñåðû èëè ãðóïïó -NR7, ãäå R7 îáîçíà÷àåò: - âîäîðîä, - ðàçâåòâëåííûé ...

Подробнее
23-11-2006 дата публикации

Non-peptidic inhibitors of akap/pka interaction

Номер: WO2006122546A1
Принадлежит: FORSCHUNGSVERBUND BERLIN E.V.

Die Erfindung betrifft nicht-peptidische Moleküle, die die Interaktion von Proteinkinase A (PKA) und Proteinkinase A-Ankerproteinen (AKAP) modulieren, insbesondere inhibieren und einen Wirts- oder Zielorganismus, der diese nicht-peptidischen Verbindungen oder Erkennungsmoleküle, die gegen diese gerichtet sind, wie z. B. Antikörper oder Chelatoren, umfasst; die Erfindung betrifft weiterhin ein pharmazeutisches Mittel, insbesondere für die Behandlung von Krankheiten, die mit einer Störung des cAMP-Signalweges assoziiert sind, insbesondere Diabetes insipidus, Hypertonie, Diabetes mellitus, Ulcus duodeni, Asthma, Herzinsuffizienz, Adipositas, AIDS, Ödeme, Leberzirrhose, Schizophrenie und andere. Die Erfindung betrifft auch die Verwendung der erfindungsgemäßen Moleküle.

Подробнее
14-03-2017 дата публикации

Biguanide derivatives, methods of preparing the same and pharmaceutical composition comprising the same

Номер: KR101715984B1

본 발명은 N4-N5-치환된 하기 화학식 1로 표시되는 바이구아나이드 유도체 또는 그의 약학적으로 허용 가능한 염, 이의 제조방법 및 이를 유효성분으로 약학 조성물을 제공한다. 본 발명의 바이구아나이드 유도체는 기존 약물에 비해 적은 양으로도 우수한 AMPKα 활성화 효과 및 암세포 증식 억제 효과를 나타내어 당뇨, 비만, 고지혈증, 고콜레스테롤혈증, 지방간, 관상동맥질환, 골다공증, 다낭성 난소증후군, 대사성 증후군, 암 등의 치료를 위해 유용하게 이용될 수 있다. [화학식 1] The present invention provides a N4-N5-substituted biaguanide derivative represented by the following formula (1), a pharmaceutically acceptable salt thereof, a process for producing the same, and a pharmaceutical composition containing the same as an active ingredient. The biguanide derivatives of the present invention exhibit the AMPKa activation effect and the cancer cell proliferation inhibitory effect which are superior to the conventional drugs in a smaller amount than those of the conventional drugs and are useful for the prevention of diabetes, obesity, hyperlipidemia, hypercholesterolemia, fatty liver, coronary artery disease, osteoporosis, polycystic ovary syndrome, Syndrome, cancer, and the like. [Chemical Formula 1]

Подробнее
02-10-2009 дата публикации

GUANIDINE-STRUCTURED COMPOUNDS AND THEIR USE AS ORGANOPOLYSILOXANE POLYCONDENSATION CATALYSTS

Номер: FR2929286A1
Принадлежит: BLUESTAR SILICONES FRANCE SAS

L'invention concerne de nouveaux composés à structure guanidine et leurs utilisations comme catalyseurs de polycondensation d'organopolysiloxanes. The invention relates to novel guanidine-structured compounds and their uses as polycondensation catalysts for organopolysiloxanes.

Подробнее
23-02-1979 дата публикации

NEW PRIMARY AMINES USEFUL FOR THE PREPARATION OF AMINOALKYL BENZENE DERIVATIVES

Номер: FR2398718A1
Автор: [UNK]
Принадлежит: Allen and Hanburys Ltd

As intermediates for the preparation of aminoalkylbenzene derivatives, compounds of the general formula II in which the substituents attached to the benzene ring are in the ortho, para or meta position with respect to one another, and in which R1 and R2, which may be identical or different, represent hydrogen or lower alkyl, cycloalkyl, aralkyl or lower alkenyl groups, or lower alkyl groups which are interrupted by an oxygen atom or a group in which R4 has the meaning hydrogen or lower alkyl, or R1 and R2 form, together with the nitrogen atom to which they are attached, a heterocyclic ring which may contain the hetero functions -O- and , represents -O-, -S-, -CH2- or , in which R5 has the meaning hydrogen or lower alkyl, m is an integer from 2 to 4, n has the value 0, 1 or 2 and Alk represents a straight-chain or branched alkylene chain having from 1 to 6 carbon atoms, and their acid addition salts with inorganic and organic acids.

Подробнее
25-08-1972 дата публикации

Zinc ethylene bis-dithiocarbamate-n-dodecylguanidine double - salts preps - fungicides

Номер: FR2121351A1
Автор: [UNK]
Принадлежит: Nippon Kayaku Co Ltd

The double salt has the formula (I): and is prepd. by dropwise addn. of a mixed soln. of ammonium ethylene-bis-dithiocarbamate and n-dodecyl-guanidine (prepd. by neutralisation of a soln. of its chloride or acetate with NaOH) to a soln. of ZnCl2 or ZnSO4. The double salt is non-phytotoxic c.f. n-dodecyl-guanidine acetate.

Подробнее
25-08-1995 дата публикации

Analogues of 15-deoxyspergualin, process for their preparation and their use in therapy

Номер: FR2716452A1
Принадлежит: Fournier Industrie et Sante SAS

La présente invention concerne en tant que produits industriels nouveaux, des composés de structure apparentée à celle de la 15-déoxyspergualine de formule: (CF DESSIN DANS BOPI) dans laquelle: A représente une liaison simple, un groupe -CH2 -, un groupe -CH2 O-, un groupe-CH2 NH-, un groupe -CH(OH)- un groupe -CHF- ou un groupe -CH(OCH3 )-, et n est égal à 6 ou 8, et leurs sels d'addition. Ces nouveaux composés sont notamment utiles en tant qu'agents immunosuppresseurs. L'invention concerne également le procédé de préparation desdits composés. The present invention relates, as new industrial products, to compounds of structure related to that of 15-deoxyspergualine of formula: (CF DRAWING IN BOPI) in which: A represents a single bond, a -CH2 - group, a - group CH2 O-, a -CH2 NH- group, a -CH (OH) group - a -CHF- group or a -CH (OCH3) - group, and n is 6 or 8, and their addition salts. These new compounds are especially useful as immunosuppressive agents. The invention also relates to the process for preparing said compounds.

Подробнее
14-11-1989 дата публикации

Process for producing iminoctadine 3-alkylbenzenesulfonates

Номер: CA1262917A
Принадлежит: Dainippon Ink and Chemicals Co Ltd

Abstract of the Disclosure A process for producing iminoctadine 3-alkyl-benzenesulfonates, which comprises reacting triamine of the formula H2N(CH2)8NH(CH2)8NH2 with an O-alkylisourea alkylbenzenesulfonate in the presence or absence of a reaction medium.

Подробнее
25-01-1995 дата публикации

Method for producing iminoctadine-3 alkylbenzene sulfonate

Номер: JPH075537B2
Принадлежит: Dainippon Ink and Chemicals Co Ltd

Подробнее
14-03-2013 дата публикации

Compositions, methods, and systems for the synthesis and use of imaging agents

Номер: CA2848147A1
Принадлежит: Lantheus Medical Imaging Inc

The present invention relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in 18 F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. In some embodiments, methods and compositions for assessing perfusion and innervation mismatch in a portion of a subject are provided.

Подробнее
02-09-2021 дата публикации

Patent JPWO2021171724A1

Номер: JPWO2021171724A1
Автор: [UNK]
Принадлежит: [UNK]

Подробнее
03-10-2017 дата публикации

N-phosphonomethylglycine guanidine derivative salts

Номер: CA2766374C

The present invention provides N-phosphonomethylglycine guanidine salts. The N-phosphonomethylglycine guanidine salts have improved herbicidal efficacy over glyphosate alone. The present invention also provides guanidine compounds and salts thereof.

Подробнее
27-10-2016 дата публикации

Compositions and methods relating to proliferative diseases

Номер: AU2016238874A1
Принадлежит: PENN STATE RESEARCH FOUNDATION

Abstract Anti-cancer compositions and methods are described herein. In particular, compositions including one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described. Methods for treatment of pathological conditions particularly cancer, in a subject using one or more of leelamine, a leelamine derivative, abietylamine, an abietylamine derivative, and an abietic acid derivative are described, herein. 2914591v1 3200 0 Body weight 2800 - DMSO (U) 2 2400 0 2.5 mg/kg (a) >10ays 61.0 % 5 mg/kg (A) E 7.5 mg/kg (+) 0 2 4 6 8 10 12 14 16 18 20 22 24 26 28 30 S.C. Cell i.p. drug Days injection injection Figure 8 30, Body weight DMSO (M) o 2000-o 6 _______________57.0% S6 10 1 1 16 2D 426 7.5 mg/kg (A) 1600-Dy 1200 5 mg/kg (a) S1200 0 2 4 6 8 10 12 14 16 18 20 22 24 26 +~D ays S.C. cell i.p. drug injection injection Figure 9

Подробнее
04-10-2007 дата публикации

Method for compressing a gaseous, oxygen-containing medium, comprises condensing the medium by means of a liquid piston containing ionic liquid

Номер: DE102006014335A1
Принадлежит: Linde GmbH

Es wird ein Verfahren zum Verdichten eines gasförmigen, Sauerstoff-enthaltenden Mediums, vorzugsweise von Sauerstoff, wobei die Verdichtung mittels eines Flüssigkeitskolbens erfolgt, sowie eine Betriebsflüssigkeit für einen Sauerstoffverdichter, in dem die Verdichtung mittels eines Flüssigkeitskolbens erfolgt, beschrieben. Erfindungsgemäß ist die Betriebsflüssigkeit eine ionische Flüssigkeit oder ein Gemisch aus zwei oder mehr unterschiedlichen ionischen Flüssigkeiten.

Подробнее
07-03-1979 дата публикации

Benzhydryl guanidine derivatives and pharmaceutical compositions

Номер: EP0000952A1
Автор: Chris Royce Rasmussen
Принадлежит: McNeil Laboratories Inc, McNeilab Inc

The invention relates to benzhydryl guanidine derivatives having the formula as defined in claim 1 and pharmaceutical compositions having hypoglycemic activity, containing such benzhydryl guanidine derivatives.

Подробнее
14-12-2006 дата публикации

Compounds and uses thereof

Номер: US20060281722A1

The invention features charge-modified antidepressants and compounds conjugated to either a charged group or a bulky group in a manner that resists in vivo cleavage. The invention provides a method for treating a patient having an inflammatory disease by administering to the patient a compound of the invention.

Подробнее
23-04-1977 дата публикации

MIXTURE WITH ANTIMICROBIAL OR PESTICIDE EFFECT

Номер: SE7511852L
Принадлежит: Kema Nord Ab

Подробнее
10-05-1997 дата публикации

Analogs of 15-desoxyispergyaline, method for its production and pharmaceutical composition on their base

Номер: RU95102479A

Изобретение относится к новым соединениям - производным 15-дезоксипергуалина общей формулыгде А обозначает простую связь, группы -CH, -CHO, группу -CHNH-, -CH(OH)-, -CHF- или группу -CH(OCH) n = 6 или 8, и их солям присоединения. Эти новые соединения особенно пригодны в качестве иммунодепрессивных агентов. Изобретение также относится к способу получения указанных соединений.

Подробнее
22-10-2015 дата публикации

Guanidine compounds and use thereof

Номер: WO2015160220A1
Принадлежит: HANALL BIOPHARMA CO., LTD.

The present invention relates to guanidine compounds for inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and use thereof. More specifically, the present invention relates to a pharmaceutical composition for preventing or treating a OXPHOS-related disease, particularly cancer by inhibiting mitochondrial oxidative phosphorylation and reprogramming cellular metabolism.

Подробнее
30-05-1988 дата публикации

Guanidinomethylbenzoic acid derivative

Номер: JPS63126860A
Автор: Toshio Sato, 利夫 佐藤

(57)【要約】本公報は電子出願前の出願データであるた め要約のデータは記録されません。

Подробнее
19-05-2016 дата публикации

Novel lipids and compositions for the delivery of therapeutics

Номер: AU2009313206B2
Принадлежит: Arbutus Biopharma Corp

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structures: (Formula (I) or (XXXV))

Подробнее
22-02-2017 дата публикации

Rapid-curing, migration-free composition based on polymers containing silane groups

Номер: EP3131992A1
Принадлежит: SIKA TECHNOLOGY AG

The invention relates to a composition comprising at least one polymer that contains silane groups and at least one catalyst of formula (I), said catalyst having specific amidine groups or guanidine groups. The composition is low in emissions and low-odour, has a good shelf-life, cures rapidly to form a mechanically high-quality, durable material with a very low propensity for migration-related defects such as exudation and dirt retention by the substrate. The composition is particularly suitable for use as an adhesive, sealant or coating.

Подробнее
21-05-2013 дата публикации

Peptidic biaryl antibacterial compounds comprising one or more basic amino acids

Номер: CA2594411C
Принадлежит: University of Wollongong

The present invention provides a compound of formula (I), (II), (III) and (IV) as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention.

Подробнее
28-09-2011 дата публикации

Novel lipids and compositions for the delivery of therapeutics

Номер: EP2367571A1
Принадлежит: Alnylam Pharmaceuticals Inc

The present invention provides lipids that are advantageously used in lipid particles for the in vivo delivery of therapeutic agents to cells. In particular, the invention provides lipids having the following structure (I) wherein R 1 and R 2 are each independently for each occurrence optionally substituted C 10 -C 30 alkyl, optionally substituted C 10 -C 30 alkenyl, optionally substituted C 10 -C 30 alkynyl, optionally substituted C 10 -C 30 acyl, or -linker-ligand; R 3 is H, optionally substituted C 1 -C 10 alkyl, optionally substituted C 2 -C 10 alkenyl, optionally substituted C 2 -C 10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonates, alkylamines, hydroxyalkyls, ω-aminoalkyls, ω -(substituted)aminoalkyls, ω-phosphoalkyls, ω -thiophosphoalkyls, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl, heterocycle, or linker-ligand; E is O, S, N(Q), C(O), N(Q)C(O), C(O)N(Q), (Q)N(CO)O, O(CO)N(Q), S(O), NS(O)2N(Q), S(O)2, N(Q)S(O)2, SS, O=N, aryl, heteroaryl, cyclic or heterocycle; and, Q is H, alkyl, ω-aminoalkyl, ω-(substituted)aminoalky, ω-phosphoalkyl or ω-thiophosphoalkyl.

Подробнее
04-07-1996 дата публикации

New peptide derivatives

Номер: AU670052B2
Принадлежит: Astra AB

Подробнее
04-12-2008 дата публикации

Peptidic Compounds

Номер: US20080300287A1
Принадлежит: University of Wollongong

The present invention provides a compound of formula (I), (II), (III) and (IV) as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention.

Подробнее
07-03-1990 дата публикации

Process for producing n,n'''-(imino-bioctamethylene)-biguanide trialkylbenzensulfonates

Номер: CN1007061B
Принадлежит: Dainippon Ink and Chemicals Co Ltd

本发明是关于一种制备N,N″′-亚氨基二-8,1-亚辛基)双胍三烷基苯磺酸盐的方法,它包括式为N 2 (CH 2 ) 8 NH(CH 2 ) 8 NH 2 的三胺与O-烷基异脲烷基苯磺酸盐在介质存在下起反应。

Подробнее
24-08-2016 дата публикации

Curable silicone coating composition

Номер: CN102959024B
Принадлежит: 3M Innovative Properties Co

本发明涉及一种可固化组合物,包含:(a)至少一种聚二有机硅氧烷、氟化聚二有机硅氧烷或它们的组合,其包含具有至少两个羟基甲硅烷基部分的反应性硅烷官能团;(b)至少一种聚二有机硅氧烷、氟化聚二有机硅氧烷或它们的组合,其包含具有至少两个氢甲硅烷基部分的反应性硅烷官能团;和(c)至少一种碱,其选自脒、胍、磷腈、前氮磷川和它们的组合;其中所述组分(a)和(b)中至少一个的平均反应性硅烷官能度为至少三。

Подробнее
16-05-2013 дата публикации

Tricyclic amino containing compounds for treatment or prevention of symptoms associated with endocrine dysfunction

Номер: CA2854836A1
Принадлежит: EMORY UNIVERSITY

The disclosure provides methods of use of certain compounds that are useful for treating certain symptoms of endocrine disturbances, and in particular those associated with hot flashes.

Подробнее
03-10-2017 дата публикации

Guanidine derivative compounds

Номер: US9775355B2
Принадлежит: MONSANTO TECHNOLOGY LLC

The present invention provides guanidine compounds and salts thereof that may be useful, for example, in the preparation of herbicidal compositions. The compounds may be used, for example, to prepare N-phosphonomethylglycine guanidine salts having improved herbicidal efficacy over glyphosate alone.

Подробнее
16-07-2009 дата публикации

Weight reducing compounds

Номер: WO2009087395A1
Принадлежит: UNIVERSITY OF STRATHCLYDE

The present invention relates to compounds which find use as weight reducing agents, and find use in treating obesity and/or excess adiposity.

Подробнее
01-06-2017 дата публикации

Guanidine compounds and uses thereof

Номер: JP2017513948A

本発明は、ミトコンドリアの酸化的リン酸化(OXPHOS)を抑制するためのグアニジン化合物及びその用途に関する。より具体的には、本発明は、ミトコンドリアの酸化的リン酸化を抑制し、細胞の代謝を再プログラミングすることにより、OXPHOSに関連する疾患、特に癌を予防又は治療するための薬学組成物に関する。【代表図】図3

Подробнее
19-11-2014 дата публикации

Compositions, methods, and systems for the synthesis and use of imaging agents

Номер: CN104159890A
Принадлежит: Lantheus Medical Imaging Inc

本发明涉及用于合成和使用显像剂或其前驱体的系统、组合物和方法。显像剂前驱体可以使用本文所述的方法转化成显像剂。在一些情况下,所述显像剂富集 18 F。在一些情况下,显像剂可以用于对个体的相关区成像,所述相关区包括(但不限于)心脏、心血管系统、心血管、脑以及其它器官。在一些实施例中,提供用于评估个体的一部分中灌注和神经支配失配的方法和组合物。

Подробнее
10-05-2022 дата публикации

Compounds useful as imaging agents, compositions comprising them, methods, and use of imaging agents

Номер: BR122019017259B1
Принадлежит: Lantheus Medical Imaging, Inc

A presente invenção refere-se a sistemas, composições, e métodos para a síntese e o uso de agentes de imageamento, ou precursores dos mesmos. Um precursor de agente de imageamento pode ser convertido em um agente de imageamento usando-se os métodos descritos nesta invenção. Em alguns casos, o agente de imageamento é rico em 18F. Em alguns casos, um agente de imageamento pode ser usado para imagear uma área de interesse em um indivíduo, incluindo, porém sem limitação, o coração, o sistema cardiovascular, os vasos cardíacos, o cérebro, e outros órgãos. Em algumas modalidades, são oferecidos métodos e composições para avaliar a incompatibilidade de perfusão e inervação em uma parte de um indivíduo. The present invention relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor can be converted to an imaging agent using the methods described in this invention. In some cases, the imaging agent is 18F rich. In some cases, an imaging agent may be used to image an area of interest in an individual, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. In some embodiments, methods and compositions are offered to assess perfusion and innervation mismatch in a part of an individual.

Подробнее
11-04-1984 дата публикации

Spergualin-related compounds, processes for the preparation thereof and their use as medicaments

Номер: EP0105193A2
Принадлежит: Microbial Chemistry Research Foundation

This invention relates to novel spergualin-related compounds of the formula (I) wherein R 1 represents a hydrogen atom, a hydroxyl group, or an aliphatic acyloxy group with 1 to 10 carbon atoms; R 2 represents a residue of an a- or ω-amino acid remaining after removing one of the hydrogen atoms from the a- or ω-amino group and the hydroxyl group from the a-carboxyl group with the proviso that R 2 does not include a residue of a-hydroxyglycine, said R 2 being attached to the adjacent carbonyl group and amino group by amide bonds; and m denotes an integer of 4 to 6, and their physiologically acceptable salts, and to a process for preparing the same. The compounds according to the present invention exhibit high stability and antitumor activity.

Подробнее